Industries > Pharma > Multiple Sclerosis Drugs Market Report 2021-2031
Multiple Sclerosis Drugs Market Report 2021-2031
By Drug Class (Corticosteroids, Interferon Beta, Sphingosine 1 Phosphate Receptor Modulators, Mixed Polymers, NF-κB Inhibitor, Pyrimidine Synthesis Inhibitor, Monoclonal Antibodies, Corticosteroids, Adrenocorticotropic Hormone, and Others), By Disease Type (Relapsing-remitting MS (RRMS), Primary-progressive MS (PPMS), Secondary-progressive MS (SPMS), and Progressive-relapsing MS (PRMS)), By Route of Administration (Parenteral, and Oral), By Drug Type (Generic Drug, and Branded Drug) By Patient Demographics (Geriatric Patient, Adult Patient, and Pediatric), By End User (Hospitals, Homecare, Specialty Clinics, Academic and Research Institute, and Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies) and Leading Regional/ Country market analysis
Multiple Sclerosis Drugs Market– our new study reveals trends, R&D progress, and predicted revenues
Where the Multiple Sclerosis Drugs is market heading? If you are involved in this sector you must read this newly updated report. Visiongain’s report shows you the potential revenues streams to 2031, assessing data, trends, opportunities, and business prospects there.
Discover how to stay ahead
Our 190+ page report provides 470+ tables and 450+ charts/graphs. Read on to discover the most lucrative areas in the industry and the future market prospects. Our new study lets you assess forecasted sales at overall world market and regional level. See financial results, trends, opportunities, and revenue predictions. Much opportunity remains in this growing Multiple Sclerosis Drugs Market. See how to exploit the opportunities.
Forecasts to 2031 and other analyses reveal the commercial prospects
• In addition to revenue forecasting to 2031, our new study provides you with recent results, growth rates, and market shares.
• You find original analyses, with business outlooks and developments.
• Discover qualitative analyses (including market dynamics, drivers, opportunities, restraints and challenges), product profiles and commercial developments.
Discover sales predictions for the world market and submarkets
• Revenue and growth forecasts from 2021 to 2031 for the Global Multiple Sclerosis Drugs Market By Drug Class
• Corticosteroids
• Interferon Beta
• Sphingosine 1 Phosphate Receptor Modulators
• Mixed Polymers
• NF-κB Inhibitor
• Pyrimidine Synthesis Inhibitor
• Monoclonal Antibodies
• Corticosteroids
• Adrenocorticotropic Hormone
• Others
• Revenue and growth forecasts from 2021 to 2031 for the Global Multiple Sclerosis Drugs Market By Disease Type
• Relapsing-remitting MS (RRMS)
• Primary-progressive MS (PPMS)
• Secondary-progressive MS (SPMS)
• Progressive-relapsing MS (PRMS)
• Revenue and growth forecasts from 2021 to 2031 for the Global Multiple Sclerosis Drugs Market By Route of Administration
• Parenteral
o Intravenous
o Subcutaneous
o Others
• Oral
• Revenue and growth forecasts from 2021 to 2031 for the Global Multiple Sclerosis Drugs Market By Drug Type
• Generic Drug
• Branded Drug
o Copaxone
o Avonex
o Gilenya
o Rebif
o Ampyra
o Betaseron
o Others
• Revenue and growth forecasts from 2021 to 2031 for the Global Multiple Sclerosis Drugs Market By Patient Demographics
• Geriatric Patient
• Adult Patient
• Pediatric
• Revenue and growth forecasts from 2021 to 2031 for the Global Multiple Sclerosis Drugs Market By End User
• Hospitals
• Homecare
• Specialty Clinics
• Academic and Research Institute
• Others
• Revenue and growth forecasts from 2021 to 2031 for the Global Multiple Sclerosis Drugs Market By Distribution Channel
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
In addition to the revenue predictions for the overall world market and segments, you will also find revenue forecasts for 5 regional and 20 leading national markets:
• North America
o U.S.
o Canada
• Europe
o Germany
o France
o United Kingdom
o Italy
o Spain
o Rest of Europe
• Asia Pacific
o China
o Japan
o India
o Australia
o South Korea
o Rest of Asia Pacific
• Latin America
o Brazil
o Mexico
o Argentina
o Rest of Latin America
• Middle East and Africa
o Turkey
o Saudi Arabia
o South Africa
o UAE
o Egypt
o Rest of Middle East and Africa
The report also includes profiles and for some of the leading companies in the Multiple Sclerosis Drugs Market, with a focus on this segment of these companies’ operations.
Leading companies and the potential for market growth
Overall world revenue for Multiple Sclerosis Drugs Market will surpass $xx million in 2021, our work calculates. We predict strong revenue growth through to 2031. Our work identifies which organizations hold the greatest potential. Discover their capabilities, progress, and commercial prospects, helping you stay ahead.
How the Multiple Sclerosis Drugs Market report helps you
In summary, our 190+ page report provides you with the following knowledge:
• Revenue forecasts to 2031 for Multiple Sclerosis Drugs Market, with forecasts for Get our report today Multiple Sclerosis Drugs Market Forecast 2021-2031: By Drug Class, Disease Type, Route of Administration, Drug Type Patient Demographics, End User, Distribution Channel and Leading Regional/ Country market analysis each forecasted at a global and regional level– discover the industry’s prospects, finding the most lucrative places for investments and revenues
• Revenue forecasts to 2031 for 5 regional and 16 key national markets – See forecasts for the Multiple Sclerosis Drugs market in North America, Europe, Asia-Pacific and Rest of the World. Also forecasted is the market in the US, Canada, Argentina, Brazil, Germany, France, UK, Italy, Spain, China, India, Japan, and Australia among other prominent economies.
• Prospects for established firms and those seeking to enter the market– including company profiles for 10 of the major companies involved in the Multiple Sclerosis Drugs Market. Some of the company’s profiled in this report include
• Bayer AG
• Teva Pharmaceutical Industries Ltd.
• Novartis AG
• F. Hoffmann-La Roche Ltd.
• Celgene Corporation
• Acorda Therapeutics, Inc.
• Sanofi
• Actelion Pharmaceuticals (Johnson & Johnson)
• EMD Serono (Merck KGaA)
• AbbVie, Inc.
Find quantitative and qualitative analyses with independent predictions. Receive information that only our report contains, staying informed with this invaluable business intelligence.
Information found nowhere else
With our newly report title, you are less likely to fall behind in knowledge or miss out on opportunities. See how our work could benefit your research, analyses, and decisions. Visiongain’s study is for everybody needing commercial analyses for the Multiple Sclerosis Drugs Market and leading companies. You will find data, trends and predictions.
Get our report today.
To access the data contained in this document please email contactus@visiongain.com
Buy our report today Multiple Sclerosis Drugs Market Report 2021-2031: By Drug Class (Corticosteroids, Interferon Beta, Sphingosine 1 Phosphate Receptor Modulators, Mixed Polymers, NF-κB Inhibitor, Pyrimidine Synthesis Inhibitor, Monoclonal Antibodies, Corticosteroids, Adrenocorticotropic Hormone, and Others), By Disease Type (Relapsing-remitting MS (RRMS), Primary-progressive MS (PPMS), Secondary-progressive MS (SPMS), and Progressive-relapsing MS (PRMS)), By Route of Administration (Parenteral, and Oral), By Drug Type (Generic Drug, and Branded Drug) By Patient Demographics (Geriatric Patient, Adult Patient, and Pediatric), By End User (Hospitals, Homecare, Specialty Clinics, Academic and Research Institute, and Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies) and Leading Regional/ Country market analysis. Avoid missing out by staying informed – order our report now.
Visiongain is a trading partner with the US Federal Government
CCR Ref number: KD4R6
Do you have any custom requirements we can help you with? Any need for a specific country, geo region, market segment or specific company information? Contact us today, we can discuss your needs and see how we can help: sara.peerun@visiongain.com
1. Report Overview
1.1. Introduction
1.2. Why You Should Read This Report
1.3. Key Questions Answered By This Analytical Report
1.4. Who is This Report For?
1.5. Methodology
1.6. Frequently Asked Questions (FAQ)
1.7. Associated Visiongain Reports
1.8. About Visiongain
2. Introduction to the Multiple Sclerosis Drugs Market
2.1. Multiple Sclerosis Drugs Market Definition
2.2. Application Submarkets Definitions
2.3. Component Submarkets Definitions
2.4. Condition Submarkets Definitions
3. Multiple Sclerosis Drugs Market Overview
3.1. Global Multiple Sclerosis Drugs Market Size and Forecast By Region
3.2. Global Multiple Sclerosis Drugs Market Share By Region
3.3. Market Dynamics
3.3.1. Market Drivers
3.3.1.1. Increasing prevalence of multiple sclerosis
3.3.1.2. Increasing research and development for multiple sclerosis drugs
3.3.1.3. Increasing geriatric population around the world
3.3.1.4. Increasing investment in multiple sclerosis drugs market
3.3.2. Market Restraints
3.3.2.1. Stringent regulation associated with product development
3.3.2.2. High cost of development
3.3.3. Opportunities
3.3.3.1. Increasing strategic initiatives in multiple sclerosis drugs
3.3.3.2. Growing regulatory approval for multiple sclerosis drugs
3.3.4. Challenges
3.3.4.1. Changes in export & import policies in developed nations
3.3.4.2. Side effects associated with the multiple sclerosis drugs
3.3.5. SWOT Analysis
3.3.5.1. Strengths
3.3.5.1.1. Strength 1
3.3.5.1.2. Strength 2
3.3.5.1.3. Strength 3
3.3.5.2. Weaknesses
3.3.5.2.1. Weakness 1
3.3.5.2.2. Weakness 2
3.3.5.2.3. Weakness 3
3.3.5.3. Opportunities
3.3.5.3.1. Opportunity 1
3.3.5.3.2. Opportunity 2
3.3.5.3.3. Opportunity 3
3.3.5.4. Threats
3.3.5.4.1. Threat 1
3.3.5.4.2. Threat 2
3.3.5.4.3. Threat 3
3.3.6. Porter’s Five Forces Analysis
3.3.6.1. Competitive Rivalry
3.3.6.2. Supplier Power
3.3.6.3. Buyer Power
3.3.6.4. Threat of Substitution
3.3.6.5. Threat of New Entry
4. Global Multiple Sclerosis Drugs Market Analysis and Forecast 2021-2031, By Drug Class (Pre COVID and V, U, W and L COVID Recovery Scenarios)
4.1. Market Overview
4.1.1. Corticosteroids
4.1.1.1. Corticosteroids market size and forecast, 2021-2031 (USD Million)
4.1.2. Interferon Beta
4.1.2.1. Interferon Beta market size and forecast, 2021-2031 (USD Million)
4.1.3. Sphingosine 1 Phosphate Receptor Modulators
4.1.3.1. Sphingosine 1 Phosphate Receptor Modulators market size and forecast, 2021-2031 (USD Million)
4.1.4. Mixed Polymers
4.1.4.1. Mixed Polymers market size and forecast, 2021-2031 (USD Million)
4.1.5. NF-κB Inhibitor
4.1.5.1. NF-κB Inhibitor market size and forecast, 2021-2031 (USD Million)
4.1.6. Pyrimidine Synthesis Inhibitor
4.1.6.1. Pyrimidine Synthesis Inhibitor market size and forecast, 2021-2031 (USD Million)
4.1.7. Monoclonal Antibodies
4.1.7.1. Monoclonal Antibodies market size and forecast, 2021-2031 (USD Million)
4.1.8. Corticosteroids
4.1.8.1. Corticosteroids market size and forecast, 2021-2031 (USD Million)
4.1.9. Adrenocorticotropic Hormone
4.1.9.1. Adrenocorticotropic hormone market size and forecast, 2021-2031 (USD Million)
4.1.10. Others
4.1.10.1. Others market size and forecast, 2021-2031 (USD Million)
5. Global Multiple Sclerosis Drugs Market Analysis and Forecast, 2021-2031 By Disease Type (Pre COVID and V, U, W and L COVID Recovery Scenarios)
5.1. Market Overview
5.1.1. Relapsing-remitting MS (RRMS)
5.1.1.1. Relapsing-remitting MS (RRMS) market size and forecast, 2021-2031 (USD Million)
5.1.2. Primary-progressive MS (PPMS)
5.1.2.1. Primary-progressive MS (PPMS) market size and forecast, 2021-2031 (USD Million)
5.1.3. Secondary-progressive MS (SPMS)
5.1.3.1. Secondary-progressive MS (SPMS) market size and forecast, 2021-2031 (USD Million)
5.1.4. Progressive-relapsing MS (PRMS)
5.1.4.1. Progressive-relapsing MS (PRMS) market size and forecast, 2021-2031 (USD Million)
6. Global Multiple Sclerosis Drugs Market Analysis and Forecast, 2021-2031 By Patient Demographics (Pre COVID and V, U, W and L COVID Recovery Scenarios)
6.1. Market Overview
6.1.1. Geriatric Patient
6.1.1.1. Geriatric Patient market size and forecast, 2021-2031 (USD Million)
6.1.2. Adult Patient
6.1.2.1. Adult Patient market size and forecast, 2021-2031 (USD Million)
6.1.3. Pediatric
6.1.3.1. Pediatric market size and forecast, 2021-2031 (USD Million)
7. Global Multiple Sclerosis Drugs Market Analysis and Forecast, 2021-2031 By Drug Type (Pre COVID and V, U, W and L COVID Recovery Scenarios)
7.1. Market Overview
7.1.1. Generic Drugs
7.1.1.1. Generic Drugs market size and forecast, 2021-2031 (USD Million)
7.1.2. Branded Drugs
7.1.2.1. Branded Drugs market size and forecast, 2021-2031 (USD Million)
8. Global Multiple Sclerosis Drugs Market Analysis and Forecast, 2021-2031 By Route of Administration (Pre COVID and V, U, W and L COVID Recovery Scenarios)
8.1. Market Overview
8.1.1. Oral
8.1.1.1. Oral market size and forecast, 2021-2031 (USD Million)
8.1.2. Parenteral
8.1.2.1. Parenteral market size and forecast, 2021-2031 (USD Million)
9. Global Multiple Sclerosis Drugs Market Analysis and Forecast, 2021-2031 By End-User (Pre COVID and V, U, W and L COVID Recovery Scenarios)
9.1. Market Overview
9.1.1. Hospitals
9.1.1.1. Hospitals market size and forecast, 2021-2031 (USD Million)
9.1.2. Homecare
9.1.2.1. Homecare market size and forecast, 2021-2031 (USD Million)
9.1.3. Specialty Clinics
9.1.3.1. Specialty Clinics market size and forecast, 2021-2031 (USD Million)
9.1.4. Others
9.1.4.1. Others market size and forecast, 2021-2031 (USD Million)
10. Global Multiple Sclerosis Drugs Market Analysis and Forecast, 2021-2031 By Distribution Channel (Pre COVID and V, U, W and L COVID Recovery Scenarios)
10.1. Market Overview
10.1.1. Hospitals Pharmacy
10.1.1.1. Hospitals Pharmacy market size and forecast, 2021-2031 (USD Million)
10.1.2. Retail Pharmacy
10.1.2.1. Retail Pharmacy market size and forecast, 2021-2031 (USD Million)
10.1.3. Online Pharmacies
10.1.3.1. Online Pharmacies market size and forecast, 2021-2031 (USD Million)
11. North America Multiple Sclerosis Drugs Market Analysis and Forecast, 2021-2031 Pre COVID and V, U, W and L COVID Recovery Scenarios)
11.1. Market Overview
11.2. North America Multiple Sclerosis Drugs Market Size and Forecast By Drug Class
11.2.1.1. XX Driving/Opportunity Factor
11.2.1.2. XX Driving/Opportunity Factor
11.3. North America Multiple Sclerosis Drugs Market Size and Forecast By Disease Type
11.3.1.1. XX Driving/Opportunity Factor
11.3.1.2. XX Driving/Opportunity Factor
11.4. North America Multiple Sclerosis Drugs Market Size and Forecast By Drug Type
11.4.1.1. XX Driving/Opportunity Factor
11.4.1.2. XX Driving/Opportunity Factor
11.5. North America Multiple Sclerosis Drugs Market Size and Forecast By Patient Demographics
11.5.1.1. XX Driving/Opportunity Factor
11.5.1.2. XX Driving/Opportunity Factor
11.6. North America Multiple Sclerosis Drugs Market Size and Forecast By Route of Administration
11.6.1.1. XX Driving/Opportunity Factor
11.6.1.2. XX Driving/Opportunity Factor
11.7. North America Multiple Sclerosis Drugs Market Size and Forecast By End-User
11.7.1.1. XX Driving/Opportunity Factor
11.7.1.2. XX Driving/Opportunity Factor
11.8. North America Multiple Sclerosis Drugs Market Size and Forecast By Distribution Channel
11.8.1.1. XX Driving/Opportunity Factor
11.8.1.2. XX Driving/Opportunity Factor
11.9. U.S. Multiple Sclerosis Drugs Market
11.9.1.1. XX Driving/Opportunity Factor
11.9.1.2. XX Driving/Opportunity Factor
11.10. Canada Multiple Sclerosis Drugs Market
11.10.1.1. XX Driving/Opportunity Factor
11.10.1.2. XX Driving/Opportunity Factor
12. Europe Multiple Sclerosis Drugs Market Analysis and Forecast, 2021-2031 (Pre COVID and V, U, W and L COVID Recovery Scenarios)
12.1. Market Overview
12.2. Europe Multiple Sclerosis Drugs Market Size and Forecast By Drug Class
12.2.1.1. XX Driving/Opportunity Factor
12.2.1.2. XX Driving/Opportunity Factor
12.3. Europe Multiple Sclerosis Drugs Market Size and Forecast By Disease Type
12.3.1.1. XX Driving/Opportunity Factor
12.3.1.2. XX Driving/Opportunity Factor
12.4. Europe Multiple Sclerosis Drugs Market Size and Forecast By Patient Demographics
12.4.1.1. XX Driving/Opportunity Factor
12.4.1.2. XX Driving/Opportunity Factor
12.5. Europe Multiple Sclerosis Drugs Market Size and Forecast By Drug Type
12.5.1.1. XX Driving/Opportunity Factor
12.5.1.2. XX Driving/Opportunity Factor
12.6. Europe Multiple Sclerosis Drugs Market Size and Forecast By Route of Administration
12.6.1.1. XX Driving/Opportunity Factor
12.6.1.2. XX Driving/Opportunity Factor
12.7. Europe Multiple Sclerosis Drugs Market Size and Forecast By End-User
12.7.1.1. XX Driving/Opportunity Factor
12.7.1.2. XX Driving/Opportunity Factor
12.8. Europe Multiple Sclerosis Drugs Market Size and Forecast By Distribution Channel
12.8.1.1. XX Driving/Opportunity Factor
12.8.1.2. XX Driving/Opportunity Factor
12.9. UK Multiple Sclerosis Drugs Market
12.9.1.1. XX Driving/Opportunity Factor
12.9.1.2. XX Driving/Opportunity Factor
12.10. Germany Multiple Sclerosis Drugs Market
12.10.1.1. XX Driving/Opportunity Factor
12.10.1.2. XX Driving/Opportunity Factor
12.11. France Multiple Sclerosis Drugs Market
12.11.1.1. XX Driving/Opportunity Factor
12.11.1.2. XX Driving/Opportunity Factor
12.12. Rest of Europe Multiple Sclerosis Drugs Market
12.12.1.1. XX Driving/Opportunity Factor
12.12.1.2. XX Driving/Opportunity Factor
13. Asia Pacific Multiple Sclerosis Drugs Market Analysis and Forecast, 2021-2031 (Pre COVID and V, U, W and L COVID Recovery Scenarios)
13.1. Market Overview
13.2. Asia-Pacific Multiple Sclerosis Drugs Market Size and Forecast By Drug Class
13.2.1.1. XX Driving/Opportunity Factor
13.2.1.2. XX Driving/Opportunity Factor
13.3. Asia-Pacific Multiple Sclerosis Drugs Market Size and Forecast By Disease Type
13.3.1.1. XX Driving/Opportunity Factor
13.3.1.2. XX Driving/Opportunity Factor
13.4. Asia-Pacific Multiple Sclerosis Drugs Market Size and Forecast By Patient Demographics
13.4.1.1. XX Driving/Opportunity Factor
13.4.1.2. XX Driving/Opportunity Factor
13.5. Asia-Pacific Multiple Sclerosis Drugs Market Size and Forecast By Drug Type
13.5.1.1. XX Driving/Opportunity Factor
13.5.1.2. XX Driving/Opportunity Factor
13.6. Asia-Pacific Multiple Sclerosis Drugs Market Size and Forecast By Route of Administration
13.6.1.1. XX Driving/Opportunity Factor
13.6.1.2. XX Driving/Opportunity Factor
13.7. Asia-Pacific Multiple Sclerosis Drugs Market Size and Forecast By End-User
13.7.1.1. XX Driving/Opportunity Factor
13.7.1.2. XX Driving/Opportunity Factor
13.8. Asia-Pacific Multiple Sclerosis Drugs Market Size and Forecast By Distribution Channel
13.8.1.1. XX Driving/Opportunity Factor
13.8.1.2. XX Driving/Opportunity Factor
13.9. China Multiple Sclerosis Drugs Market
13.9.1.1. XX Driving/Opportunity Factor
13.9.1.2. XX Driving/Opportunity Factor
13.10. India Multiple Sclerosis Drugs Market
13.10.1.1. XX Driving/Opportunity Factor
13.10.1.2. XX Driving/Opportunity Factor
13.11. Japan Multiple Sclerosis Drugs Market
13.11.1.1. XX Driving/Opportunity Factor
13.11.1.2. XX Driving/Opportunity Factor
13.12. Rest of Asia Pacific Multiple Sclerosis Drugs Market
13.12.1.1. XX Driving/Opportunity Factor
13.12.1.2. XX Driving/Opportunity Factor
14. Latin America Multiple Sclerosis Drugs Market Analysis and Forecast, 2021-2031 (Pre COVID and V, U, W and L COVID Recovery Scenarios)
14.1. Market Overview
14.2. Latin America Multiple Sclerosis Drugs Market Size and Forecast By Drug Class
14.2.1.1. XX Driving/Opportunity Factor
14.2.1.2. XX Driving/Opportunity Factor
14.3. Latin America Multiple Sclerosis Drugs Market Size and Forecast By Disease Type
14.3.1.1. XX Driving/Opportunity Factor
14.3.1.2. XX Driving/Opportunity Factor
14.4. Latin America Multiple Sclerosis Drugs Market Size and Forecast By Patient Demographics
14.4.1.1. XX Driving/Opportunity Factor
14.4.1.2. XX Driving/Opportunity Factor
14.5. Latin America Multiple Sclerosis Drugs Market Size and Forecast By Drug Type
14.5.1.1. XX Driving/Opportunity Factor
14.5.1.2. XX Driving/Opportunity Factor
14.6. Latin America Multiple Sclerosis Drugs Market Size and Forecast By Route of Administration
14.6.1.1. XX Driving/Opportunity Factor
14.6.1.2. XX Driving/Opportunity Factor
14.7. Latin America Multiple Sclerosis Drugs Market Size and Forecast By End-User
14.7.1.1. XX Driving/Opportunity Factor
14.7.1.2. XX Driving/Opportunity Factor
14.8. Latin America Multiple Sclerosis Drugs Market Size and Forecast By Distribution Channel
14.9. Brazil Multiple Sclerosis Drugs Market
14.9.1.1. XX Driving/Opportunity Factor
14.9.1.2. XX Driving/Opportunity Factor
14.10. Mexico Multiple Sclerosis Drugs Market
14.10.1.1. XX Driving/Opportunity Factor
14.10.1.2. XX Driving/Opportunity Factor
14.11. Rest of Latin America Multiple Sclerosis Drugs Market
14.11.1.1. XX Driving/Opportunity Factor
14.11.1.2. XX Driving/Opportunity Factor
15. MEA Multiple Sclerosis Drugs Market Analysis and Forecast, 2021-2031 (Pre COVID and V, U, W and L COVID Recovery Scenarios)
15.1. Market Overview
15.2. MEA Multiple Sclerosis Drugs Market Size and Forecast By Drug Class
15.2.1.1. XX Driving/Opportunity Factor
15.2.1.2. XX Driving/Opportunity Factor
15.3. MEA Multiple Sclerosis Drugs Market Size and Forecast By Disease Type
15.3.1.1. XX Driving/Opportunity Factor
15.3.1.2. XX Driving/Opportunity Factor
15.4. MEA Multiple Sclerosis Drugs Market Size and Forecast By Patient Demographics
15.4.1.1. XX Driving/Opportunity Factor
15.4.1.2. XX Driving/Opportunity Factor
15.5. MEA Multiple Sclerosis Drugs Market Size and Forecast By Drug Type
15.5.1.1. XX Driving/Opportunity Factor
15.5.1.2. XX Driving/Opportunity Factor
15.6. MEA Multiple Sclerosis Drugs Market Size and Forecast By Route of Administration
15.6.1.1. XX Driving/Opportunity Factor
15.6.1.2. XX Driving/Opportunity Factor
15.7. MEA Multiple Sclerosis Drugs Market Size and Forecast By End-User
15.7.1.1. XX Driving/Opportunity Factor
15.7.1.2. XX Driving/Opportunity Factor
15.8. MEA Multiple Sclerosis Drugs Market Size and Forecast By Distribution Channel
15.8.1.1. XX Driving/Opportunity Factor
15.8.1.2. XX Driving/Opportunity Factor
15.9. GCC Multiple Sclerosis Drugs Market
15.9.1.1. XX Driving/Opportunity Factor
15.9.1.2. XX Driving/Opportunity Factor
15.10. South Africa Multiple Sclerosis Drugs Market
15.10.1.1. XX Driving/Opportunity Factor
15.10.1.2. XX Driving/Opportunity Factor
15.11. Rest of MEA Multiple Sclerosis Drugs Market
15.11.1.1. XX Driving/Opportunity Factor
15.11.1.2. XX Driving/Opportunity Factor
16. Companies in the Multiple Sclerosis Drugs Market
16.1. Shire Plc
16.1.1. Company Snapshot
16.1.2. Company Overview
16.1.3. Financial Performance (2015-2019)
16.1.3.1. Net Revenue
16.1.3.2. Gross Profit
16.1.3.3. Geographical Revenue, 2019
16.1.4. Product Offerings
16.1.5. Recent Initiatives (2017-2019)
16.2. BioCryst Pharmaceuticals, Inc.
16.2.1. Company Snapshot
16.2.2. Company Overview
16.2.3. Financial Performance (2015-2019)
16.2.3.1. Net Revenue
16.2.3.2. Gross Profit
16.2.3.3. Geographical Revenue, 2019
16.2.4. Product Offerings
16.2.5. Recent Initiatives (2017-2019)
16.3. Ionis Pharmaceuticals, Inc.
16.3.1. Company Snapshot
16.3.2. Company Overview
16.3.3. Financial Performance (2015-2019)
16.3.3.1. Net Revenue
16.3.3.2. Gross Profit
16.3.3.3. Geographical Revenue, 2019
16.3.4. Product Offerings
16.3.5. Recent Initiatives (2017-2019)
16.4. Pharming Group N.V.
16.4.1. Company Snapshot
16.4.2. Company Overview
16.4.3. Financial Performance (2015-2019)
16.4.3.1. Net Revenue
16.4.3.2. Gross Profit
16.4.3.3. Geographical Revenue, 2019
16.4.4. Product Offerings
16.4.5. Recent Initiatives (2017-2019)
16.5. CSL Limited
16.5.1. Company Snapshot
16.5.2. Company Overview
16.5.3. Financial Performance (2015-2019)
16.5.3.1. Net Revenue
16.5.3.2. Gross Profit
16.5.3.3. Geographical Revenue, 2019
16.5.4. Product Offerings
16.5.5. Recent Initiatives (2017-2019)
16.6. Attune Pharmaceuticals, Inc.
16.6.1. Company Snapshot
16.6.2. Company Overview
16.6.3. Financial Performance (2015-2019)
16.6.3.1. Net Revenue
16.6.3.2. Gross Profit
16.6.3.3. Geographical Revenue, 2019
16.6.4. Product Offerings
16.6.5. Recent Initiatives (2017-2019)
16.7. Adverum Biotechnologies, Inc.
16.7.1. Company Snapshot
16.7.2. Company Overview
16.7.3. Financial Performance (2015-2019)
16.7.3.1. Net Revenue
16.7.3.2. Gross Profit
16.7.3.3. Geographical Revenue, 2019
16.7.4. Product Offerings
16.7.5. Recent Initiatives (2017-2019)
16.8. KalVista Pharmaceuticals, Inc.
16.8.1. Company Snapshot
16.8.2. Company Overview
16.8.3. Financial Performance (2015-2019)
16.8.3.1. Net Revenue
16.8.3.2. Gross Profit
16.8.3.3. Geographical Revenue, 2019
16.8.4. Product Offerings
16.8.5. Recent Initiatives (2017-2019)
16.9. Takeda Pharmaceutical Company Limited
16.9.1. Company Snapshot
16.9.2. Company Overview
16.9.3. Financial Performance (2015-2019)
16.9.3.1. Net Revenue
16.9.3.2. Gross Profit
16.9.3.3. Geographical Revenue, 2019
16.9.4. Product Offerings
16.9.5. Recent Initiatives (2017-2019)
16.10. Pharming Healthcare, Inc.
16.10.1. Company Snapshot
16.10.2. Company Overview
16.10.3. Financial Performance (2015-2019)
16.10.3.1. Net Revenue
16.10.3.2. Gross Profit
16.10.3.3. Geographical Revenue, 2019
16.10.4. Product Offerings
16.10.5. Recent Initiatives (2017-2019)
16.11. Other Notable Players
17. Conclusion
18. Glossary
Associated Visiongain Reports
Visiongain Report Sales Order Form
Appendix A
About Visiongain
Appendix B
Visiongain report evaluation form
LIST OF TABLES
Table 1. Multiple Sclerosis Drugs Market Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 2. Multiple Sclerosis Drugs Market Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 3. Multiple Sclerosis Drugs Market Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 4. Multiple Sclerosis Drugs Market Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 5. Multiple Sclerosis Drugs Market Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 6. Multiple Sclerosis Drugs Market Drivers & Restraints 2021
Table 7. Multiple Sclerosis Drugs Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 8. Multiple Sclerosis Drugs Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 9. Multiple Sclerosis Drugs Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 10. Multiple Sclerosis Drugs Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 11. Multiple Sclerosis Drugs Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 12. Corticosteroids Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 13. Corticosteroids Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 14. Corticosteroids Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 15. Corticosteroids Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 16. Corticosteroids Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 17. Interferon Beta Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 18. Interferon Beta Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 19. Interferon Beta Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 20. Interferon Beta Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 21. Interferon Beta Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 22. Sphingosine 1 Phosphate Receptor Modulators Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 23. Sphingosine 1 Phosphate Receptor Modulators Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 24. Sphingosine 1 Phosphate Receptor Modulators Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 25. Sphingosine 1 Phosphate Receptor Modulators Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 26. Sphingosine 1 Phosphate Receptor Modulators Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 27. Mixed Polymers Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 28. Mixed Polymers Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 29. Mixed Polymers Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 30. Mixed Polymers Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 31. Mixed Polymers Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 32. NF-κB Inhibitor Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 33. NF-κB Inhibitor Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 34. NF-κB Inhibitor Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 35. NF-κB Inhibitor Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 36. NF-κB Inhibitor Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 37. Pyrimidine Synthesis Inhibitor Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 38. Pyrimidine Synthesis Inhibitor Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 39. Pyrimidine Synthesis Inhibitor Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 40. Pyrimidine Synthesis Inhibitor Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 41. Pyrimidine Synthesis Inhibitor Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 42. Monoclonal Antibodies Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 43. Monoclonal Antibodies Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 44. Monoclonal Antibodies Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 45. Monoclonal Antibodies Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 46. Monoclonal Antibodies Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 47. Adrenocorticotropic Hormone Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 48. Adrenocorticotropic Hormone Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 49. Adrenocorticotropic Hormone Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 50. Adrenocorticotropic Hormone Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 51. Adrenocorticotropic Hormone Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 52. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 53. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 54. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 55. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 56. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 57. Multiple Sclerosis Drugs Market Forecast By Disease Type 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 58. Multiple Sclerosis Drugs Market Forecast By Disease Type 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 59. Multiple Sclerosis Drugs Market Forecast By Disease Type 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 60. Multiple Sclerosis Drugs Market Forecast By Disease Type 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 61. Multiple Sclerosis Drugs Market Forecast By Disease Type 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 62. Relapsing-remitting MS (RRMS) Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 63. Relapsing-remitting MS (RRMS) Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 64. Relapsing-remitting MS (RRMS) Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 65. Relapsing-remitting MS (RRMS) Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 66. Relapsing-remitting MS (RRMS) Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 67. Primary-progressive MS (PPMS) Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 68. Primary-progressive MS (PPMS) Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 69. Primary-progressive MS (PPMS) Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 70. Primary-progressive MS (PPMS) Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 71. Primary-progressive MS (PPMS) Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 72. Secondary-progressive MS (SPMS) Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 73. Secondary-progressive MS (SPMS) Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 74. Secondary-progressive MS (SPMS) Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 75. Secondary-progressive MS (SPMS) Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 76. Secondary-progressive MS (SPMS) Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 77. Progressive-relapsing MS (PRMS) Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 78. Progressive-relapsing MS (PRMS) Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 79. Progressive-relapsing MS (PRMS) Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 80. Progressive-relapsing MS (PRMS) Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 81. Progressive-relapsing MS (PRMS) Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 82. Multiple Sclerosis Drugs Market Forecast By Patient Demographics 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 83. Multiple Sclerosis Drugs Market Forecast By Patient Demographics 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 84. Multiple Sclerosis Drugs Market Forecast By Patient Demographics 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 85. Multiple Sclerosis Drugs Market Forecast By Patient Demographics 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 86. Multiple Sclerosis Drugs Market Forecast By Patient Demographics 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 87. Geriatric Patient Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 88. Geriatric Patient Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 89. Geriatric Patient Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 90. Geriatric Patient Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 91. Geriatric Patient Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 92. Adult Patient Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 93. Adult Patient Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 94. Adult Patient Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 95. Adult Patient Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 96. Adult Patient Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 97. Pediatric Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 98. Pediatric Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 99. Pediatric Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 100. Pediatric Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 101. Pediatric Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 102. Multiple Sclerosis Drugs Market Forecast By Route of Administration 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 103. Multiple Sclerosis Drugs Market Forecast By Route of Administration 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 104. Multiple Sclerosis Drugs Market Forecast By Route of Administration 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 105. Multiple Sclerosis Drugs Market Forecast By Route of Administration 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 106. Multiple Sclerosis Drugs Market Forecast By Route of Administration 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 107. Oral Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 108. Oral Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 109. Oral Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 110. Oral Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 111. Oral Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 112. Parenteral Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 113. Parenteral Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 114. Parenteral Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 115. Parenteral Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 116. Parenteral Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 117. Multiple Sclerosis Drugs Market Forecast By Drug Type 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 118. Multiple Sclerosis Drugs Market Forecast By Drug Type 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 119. Multiple Sclerosis Drugs Market Forecast By Drug Type 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 120. Multiple Sclerosis Drugs Market Forecast By Drug Type 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 121. Multiple Sclerosis Drugs Market Forecast By Drug Type 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 122. Generic Drugs Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 123. Generic Drugs Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 124. Generic Drugs Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 125. Generic Drugs Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 126. Generic Drugs Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 127. Branded Drugs Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 128. Branded Drugs Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 129. Branded Drugs Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 130. Branded Drugs Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 131. Branded Drugs Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 132. Multiple Sclerosis Drugs Market Forecast By End-User 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 133. Multiple Sclerosis Drugs Market Forecast By End-User 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 134. Multiple Sclerosis Drugs Market Forecast By End-User 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 135. Multiple Sclerosis Drugs Market Forecast By End-User 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 136. Multiple Sclerosis Drugs Market Forecast By End-User 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 137. Hospitals Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 138. Hospitals Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 139. Hospitals Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 140. Hospitals Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 141. Hospitals Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 142. Homecare Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 143. Homecare Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 144. Homecare Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 145. Homecare Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 146. Homecare Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 147. Specialty Clinics Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 148. Specialty Clinics Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 149. Specialty Clinics Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 150. Specialty Clinics Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 151. Specialty Clinics Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 152. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 153. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 154. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 155. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 156. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 157. Multiple Sclerosis Drugs Market Forecast By Distribution Channel 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 158. Multiple Sclerosis Drugs Market Forecast By Distribution Channel 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 159. Multiple Sclerosis Drugs Market Forecast By Distribution Channel 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 160. Multiple Sclerosis Drugs Market Forecast By Distribution Channel 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 161. Multiple Sclerosis Drugs Market Forecast By Distribution Channel 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 162. Hospital Pharmacy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 163. Hospital Pharmacy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 164. Hospital Pharmacy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 165. Hospital Pharmacy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 166. Hospital Pharmacy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 167. Retail Pharmacy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 168. Retail Pharmacy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 169. Retail Pharmacy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 170. Retail Pharmacy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 171. Retail Pharmacy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 172. Online Pharmacies Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 173. Online Pharmacies Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 174. Online Pharmacies Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 175. Online Pharmacies Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 176. Online Pharmacies Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 177. North America Multiple Sclerosis Drugs Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 178. North America Multiple Sclerosis Drugs Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 179. North America Multiple Sclerosis Drugs Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 180. North America Multiple Sclerosis Drugs Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 181. North America Multiple Sclerosis Drugs Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 182. North America Multiple Sclerosis Drugs Market Forecast By Disease Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 183. North America Multiple Sclerosis Drugs Market Forecast By Disease Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 184. North America Multiple Sclerosis Drugs Market Forecast By Disease Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 185. North America Multiple Sclerosis Drugs Market Forecast By Disease Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 186. North America Multiple Sclerosis Drugs Market Forecast By Disease Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 187. North America Multiple Sclerosis Drugs Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 188. North America Multiple Sclerosis Drugs Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 189. North America Multiple Sclerosis Drugs Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 190. North America Multiple Sclerosis Drugs Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 191. North America Multiple Sclerosis Drugs Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 192. North America Multiple Sclerosis Drugs Market Forecast By Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 193. North America Multiple Sclerosis Drugs Market Forecast By Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 194. North America Multiple Sclerosis Drugs Market Forecast By Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 195. North America Multiple Sclerosis Drugs Market Forecast By Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 196. North America Multiple Sclerosis Drugs Market Forecast By Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 197. North America Multiple Sclerosis Drugs Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 198. North America Multiple Sclerosis Drugs Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 199. North America Multiple Sclerosis Drugs Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 200. North America Multiple Sclerosis Drugs Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 201. North America Multiple Sclerosis Drugs Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 202. North America Multiple Sclerosis Drugs Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 203. North America Multiple Sclerosis Drugs Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 204. North America Multiple Sclerosis Drugs Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 205. North America Multiple Sclerosis Drugs Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 206. North America Multiple Sclerosis Drugs Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 207. North America Multiple Sclerosis Drugs Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 208. North America Multiple Sclerosis Drugs Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 209. North America Multiple Sclerosis Drugs Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 210. North America Multiple Sclerosis Drugs Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 211. North America Multiple Sclerosis Drugs Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 212. North America Multiple Sclerosis Drugs Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 213. North America Multiple Sclerosis Drugs Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 214. North America Multiple Sclerosis Drugs Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 215. North America Multiple Sclerosis Drugs Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 216. North America Multiple Sclerosis Drugs Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 217. US Multiple Sclerosis Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 218. US Multiple Sclerosis Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 219. US Multiple Sclerosis Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 220. US Multiple Sclerosis Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 221. US Multiple Sclerosis Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 222. Canada Multiple Sclerosis Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 223. Canada Multiple Sclerosis Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 224. Canada Multiple Sclerosis Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 225. Canada Multiple Sclerosis Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 226. Canada Multiple Sclerosis Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 227. Europe Multiple Sclerosis Drugs Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (Before COVID) Table 82.
Table 228. Europe Multiple Sclerosis Drugs Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 229. Europe Multiple Sclerosis Drugs Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 230. Europe Multiple Sclerosis Drugs Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 231. Europe Multiple Sclerosis Drugs Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 232. Europe Multiple Sclerosis Drugs Market Forecast By Disease Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 233. Europe Multiple Sclerosis Drugs Market Forecast By Disease Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 234. Europe Multiple Sclerosis Drugs Market Forecast By Disease Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 235. Europe Multiple Sclerosis Drugs Market Forecast By Disease Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 236. Europe Multiple Sclerosis Drugs Market Forecast By Disease Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 237. Europe Multiple Sclerosis Drugs Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 238. Europe Multiple Sclerosis Drugs Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 239. Europe Multiple Sclerosis Drugs Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 240. Europe Multiple Sclerosis Drugs Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 241. Europe Multiple Sclerosis Drugs Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 242. Europe Multiple Sclerosis Drugs Market Forecast By Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 243. Europe Multiple Sclerosis Drugs Market Forecast By Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 244. Europe Multiple Sclerosis Drugs Market Forecast By Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 245. Europe Multiple Sclerosis Drugs Market Forecast By Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 246. Europe Multiple Sclerosis Drugs Market Forecast By Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 247. Europe Multiple Sclerosis Drugs Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 248. Europe Multiple Sclerosis Drugs Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 249. Europe Multiple Sclerosis Drugs Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 250. Europe Multiple Sclerosis Drugs Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 251. Europe Multiple Sclerosis Drugs Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 252. Europe Multiple Sclerosis Drugs Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 253. Europe Multiple Sclerosis Drugs Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 254. Europe Multiple Sclerosis Drugs Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 255. Europe Multiple Sclerosis Drugs Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 256. Europe Multiple Sclerosis Drugs Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 257. Europe Multiple Sclerosis Drugs Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 258. Europe Multiple Sclerosis Drugs Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 259. Europe Multiple Sclerosis Drugs Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 260. Europe Multiple Sclerosis Drugs Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 261. Europe Multiple Sclerosis Drugs Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 262. Europe Multiple Sclerosis Drugs Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 263. Europe Multiple Sclerosis Drugs Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 264. Europe Multiple Sclerosis Drugs Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 265. Europe Multiple Sclerosis Drugs Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 266. UK Multiple Sclerosis Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 267. UK Multiple Sclerosis Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 268. UK Multiple Sclerosis Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 269. UK Multiple Sclerosis Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 270. UK Multiple Sclerosis Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 271. Germany Multiple Sclerosis Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 272. Germany Multiple Sclerosis Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 273. Germany Multiple Sclerosis Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 274. Germany Multiple Sclerosis Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 275. Germany Multiple Sclerosis Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 276. France Multiple Sclerosis Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 277. France Multiple Sclerosis Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 278. France Multiple Sclerosis Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 279. France Multiple Sclerosis Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 280. France Multiple Sclerosis Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 281. Rest of Europe Multiple Sclerosis Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 282. Rest of Europe Multiple Sclerosis Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 283. Rest of Europe Multiple Sclerosis Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 284. Rest of Europe Multiple Sclerosis Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 285. Rest of Europe Multiple Sclerosis Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 286. Asia Pacific Multiple Sclerosis Drugs Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 287. Asia Pacific Multiple Sclerosis Drugs Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 288. Asia Pacific Multiple Sclerosis Drugs Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 289. Asia Pacific Multiple Sclerosis Drugs Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 290. Asia Pacific Multiple Sclerosis Drugs Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 291. Asia Pacific Multiple Sclerosis Drugs Market Forecast By Disease Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 292. Asia Pacific Multiple Sclerosis Drugs Market Forecast By Disease Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 293. Asia Pacific Multiple Sclerosis Drugs Market Forecast By Disease Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 294. Asia Pacific Multiple Sclerosis Drugs Market Forecast By Disease Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 295. Asia Pacific Multiple Sclerosis Drugs Market Forecast By Disease Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 296. Asia Pacific Multiple Sclerosis Drugs Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 297. Asia Pacific Multiple Sclerosis Drugs Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 298. Asia Pacific Multiple Sclerosis Drugs Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 299. Asia Pacific Multiple Sclerosis Drugs Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 300. Asia Pacific Multiple Sclerosis Drugs Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 301. Asia Pacific Multiple Sclerosis Drugs Market Forecast By Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 302. Asia Pacific Multiple Sclerosis Drugs Market Forecast By Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 303. Asia Pacific Multiple Sclerosis Drugs Market Forecast By Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 304. Asia Pacific Multiple Sclerosis Drugs Market Forecast By Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 305. Asia Pacific Multiple Sclerosis Drugs Market Forecast By Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 306. Asia Pacific Multiple Sclerosis Drugs Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 307. Asia Pacific Multiple Sclerosis Drugs Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 308. Asia Pacific Multiple Sclerosis Drugs Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 309. Asia Pacific Multiple Sclerosis Drugs Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 310. Asia Pacific Multiple Sclerosis Drugs Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 311. Asia Pacific Multiple Sclerosis Drugs Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 312. Asia Pacific Multiple Sclerosis Drugs Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 313. Asia Pacific Multiple Sclerosis Drugs Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 314. Asia Pacific Multiple Sclerosis Drugs Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 315. Asia Pacific Multiple Sclerosis Drugs Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 316. Asia Pacific Multiple Sclerosis Drugs Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 317. Asia Pacific Multiple Sclerosis Drugs Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 318. Asia Pacific Multiple Sclerosis Drugs Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 319. Asia Pacific Multiple Sclerosis Drugs Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 320. Asia Pacific Multiple Sclerosis Drugs Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 321. Asia Pacific Multiple Sclerosis Drugs Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 322. Asia Pacific Multiple Sclerosis Drugs Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 323. Asia Pacific Multiple Sclerosis Drugs Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 324. Asia Pacific Multiple Sclerosis Drugs Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 325. Asia Pacific Multiple Sclerosis Drugs Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 326. China Multiple Sclerosis Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 327. China Multiple Sclerosis Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 328. China Multiple Sclerosis Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 329. China Multiple Sclerosis Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 330. China Multiple Sclerosis Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 331. India Multiple Sclerosis Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 332. India Multiple Sclerosis Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 333. India Multiple Sclerosis Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 334. India Multiple Sclerosis Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 335. India Multiple Sclerosis Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 336. Japan Multiple Sclerosis Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 337. Japan Multiple Sclerosis Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 338. Japan Multiple Sclerosis Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 339. Japan Multiple Sclerosis Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 340. Japan Multiple Sclerosis Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 341. RoAPAC Multiple Sclerosis Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 342. RoAPAC Multiple Sclerosis Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 343. RoAPAC Multiple Sclerosis Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 344. RoAPAC Multiple Sclerosis Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 345. RoAPAC Multiple Sclerosis Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 346. Middle East Multiple Sclerosis Drugs Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 347. Middle East Multiple Sclerosis Drugs Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 348. Middle East Multiple Sclerosis Drugs Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 349. Middle East Multiple Sclerosis Drugs Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 350. Middle East Multiple Sclerosis Drugs Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 351. Middle East Multiple Sclerosis Drugs Market Forecast By Disease Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 352. Middle East Multiple Sclerosis Drugs Market Forecast By Disease Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 353. Middle East Multiple Sclerosis Drugs Market Forecast By Disease Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 354. Middle East Multiple Sclerosis Drugs Market Forecast By Disease Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 355. Middle East Multiple Sclerosis Drugs Market Forecast By Disease Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 356. Middle East Multiple Sclerosis Drugs Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 357. Middle East Multiple Sclerosis Drugs Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 358. Middle East Multiple Sclerosis Drugs Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 359. Middle East Multiple Sclerosis Drugs Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 360. Middle East Multiple Sclerosis Drugs Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 361. Middle East Multiple Sclerosis Drugs Market Forecast By Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 362. Middle East Multiple Sclerosis Drugs Market Forecast By Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 363. Middle East Multiple Sclerosis Drugs Market Forecast By Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 364. Middle East Multiple Sclerosis Drugs Market Forecast By Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 365. Middle East Multiple Sclerosis Drugs Market Forecast By Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 366. Middle East Multiple Sclerosis Drugs Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 367. Middle East Multiple Sclerosis Drugs Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 368. Middle East Multiple Sclerosis Drugs Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 369. Middle East Multiple Sclerosis Drugs Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 370. Middle East Multiple Sclerosis Drugs Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 371. Middle East Multiple Sclerosis Drugs Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 372. Middle East Multiple Sclerosis Drugs Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 373. Middle East Multiple Sclerosis Drugs Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 374. Middle East Multiple Sclerosis Drugs Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 375. Middle East Multiple Sclerosis Drugs Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 376. Middle East Multiple Sclerosis Drugs Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 377. Middle East Multiple Sclerosis Drugs Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 378. Middle East Multiple Sclerosis Drugs Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 379. Middle East Multiple Sclerosis Drugs Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 380. Middle East Multiple Sclerosis Drugs Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 381. Latin America Multiple Sclerosis Drugs Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 382. Latin America Multiple Sclerosis Drugs Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 383. Latin America Multiple Sclerosis Drugs Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 384. Latin America Multiple Sclerosis Drugs Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 385. Latin America Multiple Sclerosis Drugs Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 386. Latin America Multiple Sclerosis Drugs Market Forecast By Disease Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 387. Latin America Multiple Sclerosis Drugs Market Forecast By Disease Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 388. Latin America Multiple Sclerosis Drugs Market Forecast By Disease Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 389. Latin America Multiple Sclerosis Drugs Market Forecast By Disease Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 390. Latin America Multiple Sclerosis Drugs Market Forecast By Disease Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 391. Latin America Multiple Sclerosis Drugs Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 392. Latin America Multiple Sclerosis Drugs Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 393. Latin America Multiple Sclerosis Drugs Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 394. Latin America Multiple Sclerosis Drugs Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 395. Latin America Multiple Sclerosis Drugs Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 396. Latin America Multiple Sclerosis Drugs Market Forecast By Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 397. Latin America Multiple Sclerosis Drugs Market Forecast By Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 398. Latin America Multiple Sclerosis Drugs Market Forecast By Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 399. Latin America Multiple Sclerosis Drugs Market Forecast By Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 400. Latin America Multiple Sclerosis Drugs Market Forecast By Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 401. Latin America Multiple Sclerosis Drugs Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 402. Latin America Multiple Sclerosis Drugs Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 403. Latin America Multiple Sclerosis Drugs Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 404. Latin America Multiple Sclerosis Drugs Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 405. Latin America Multiple Sclerosis Drugs Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 406. Latin America Multiple Sclerosis Drugs Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 407. Latin America Multiple Sclerosis Drugs Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 408. Latin America Multiple Sclerosis Drugs Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 409. Latin America Multiple Sclerosis Drugs Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 410. Latin America Multiple Sclerosis Drugs Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 411. Latin America Multiple Sclerosis Drugs Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 412. Latin America Multiple Sclerosis Drugs Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 413. Latin America Multiple Sclerosis Drugs Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 414. Latin America Multiple Sclerosis Drugs Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 415. Latin America Multiple Sclerosis Drugs Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 416. Africa Multiple Sclerosis Drugs Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 417. Africa Multiple Sclerosis Drugs Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 418. Africa Multiple Sclerosis Drugs Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 419. Africa Multiple Sclerosis Drugs Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 420. Africa Multiple Sclerosis Drugs Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 421. Africa Multiple Sclerosis Drugs Market Forecast By Disease Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 422. Africa Multiple Sclerosis Drugs Market Forecast By Disease Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 423. Africa Multiple Sclerosis Drugs Market Forecast By Disease Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 424. Africa Multiple Sclerosis Drugs Market Forecast By Disease Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 425. Africa Multiple Sclerosis Drugs Market Forecast By Disease Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 426. Africa Multiple Sclerosis Drugs Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 427. Africa Multiple Sclerosis Drugs Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 428. Africa Multiple Sclerosis Drugs Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 429. Africa Multiple Sclerosis Drugs Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 430. Africa Multiple Sclerosis Drugs Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 431. Africa Multiple Sclerosis Drugs Market Forecast By Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 432. Africa Multiple Sclerosis Drugs Market Forecast By Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 433. Africa Multiple Sclerosis Drugs Market Forecast By Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 434. Africa Multiple Sclerosis Drugs Market Forecast By Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 435. Africa Multiple Sclerosis Drugs Market Forecast By Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 436. Africa Multiple Sclerosis Drugs Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 437. Africa Multiple Sclerosis Drugs Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 438. Africa Multiple Sclerosis Drugs Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 439. Africa Multiple Sclerosis Drugs Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 440. Africa Multiple Sclerosis Drugs Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 441. Africa Multiple Sclerosis Drugs Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 442. Africa Multiple Sclerosis Drugs Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 443. Africa Multiple Sclerosis Drugs Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 444. Africa Multiple Sclerosis Drugs Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 445. Africa Multiple Sclerosis Drugs Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 446. Africa Multiple Sclerosis Drugs Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 447. Africa Multiple Sclerosis Drugs Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 448. Africa Multiple Sclerosis Drugs Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 449. Africa Multiple Sclerosis Drugs Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 450. Africa Multiple Sclerosis Drugs Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 451. Leading 10 Multiple Sclerosis Drugs Companies (Ranking, Company, Latest Total Company Sales US$M*, HQ)
Table 452. Shire PlcProfile 2019 (CEO, HQ, Founded, Website)
Table 453. Shire Plc Multiple Sclerosis Drugs Product Offering (Segment, Product Offerings)
Table 454. BioCryst Pharmaceuticals, Inc. Profile 2019 (CEO, HQ, Founded, Website)
Table 455. BioCryst Pharmaceuticals, Inc. Multiple Sclerosis Drugs Product Offering (Segment, Product Offerings)
Table 456. Ionis Pharmaceuticals, Inc. Profile 2019 (CEO, HQ, Founded, Website)
Table 457. Ionis Pharmaceuticals, Inc..Multiple Sclerosis Drugs Product Offering (Segment, Product Offerings)
Table 458. Pharming Group N.V. Profile 2019 (CEO, HQ, Founded, Website)
Table 459. Pharming Group N.V. Multiple Sclerosis Drugs Product Offering (Segment, Product Offerings)
Table 460. CSL Limited Profile 2019 (CEO, HQ, Founded, Website)
Table 461. CSL Limited Multiple Sclerosis Drugs Product Offering (Segment, Product Offerings)
Table 462. Attune Pharmaceuticals, Inc. Profile 2019 (CEO, HQ, Founded, Website)
Table 463. Attune Pharmaceuticals, Inc. Multiple Sclerosis Drugs Product Offering (Segment, Product Offerings)
Table 464. Adverum Biotechnologies, Inc. Profile 2019 (CEO, HQ, Founded, Website)
Table 465. Adverum Biotechnologies, Inc. Multiple Sclerosis Drugs Product Offering (Segment, Product Offerings)
Table 466. KalVista Pharmaceuticals, Inc. Profile 2019 (CEO, HQ, Founded, Website)
Table 467. KalVista Pharmaceuticals, Inc. Multiple Sclerosis Drugs Product Offering (Segment, Product Offerings)
Table 468. Takeda Pharmaceutical Company Limited Profile 2019 (CEO, HQ, Founded, Website)
Table 469. Takeda Pharmaceutical Company Limited Multiple Sclerosis Drugs Product Offering (Segment, Product Offerings)
Table 470. Pharming Healthcare, Inc. Corporation Profile 2019 (CEO, HQ, Founded, Website)
Table 471. Pharming Healthcare, Inc. Multiple Sclerosis Drugs Product Offering (Segment, Product Offerings)
Table 472. Other Companies Involved in the Multiple Sclerosis Drugs Market 2021 (Company, Location)
LIST OF FIGURES
Figure 1. Multiple Sclerosis Drugs Market Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 2. Multiple Sclerosis Drugs Market Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 3. Multiple Sclerosis Drugs Market Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 4. Multiple Sclerosis Drugs Market Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 5. Multiple Sclerosis Drugs Market Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 6. Multiple Sclerosis Drugs Market Drivers & Restraints 2021
Figure 7. Multiple Sclerosis Drugs Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 8. Multiple Sclerosis Drugs Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 9. Multiple Sclerosis Drugs Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 10. Multiple Sclerosis Drugs Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 11. Multiple Sclerosis Drugs Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 12. Corticosteroids Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 13. Corticosteroids Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 14. Corticosteroids Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 15. Corticosteroids Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 16. Corticosteroids Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 17. Interferon Beta Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 18. Interferon Beta Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 19. Interferon Beta Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 20. Interferon Beta Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 21. Interferon Beta Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 22. Sphingosine 1 Phosphate Receptor Modulators Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 23. Sphingosine 1 Phosphate Receptor Modulators Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 24. Sphingosine 1 Phosphate Receptor Modulators Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 25. Sphingosine 1 Phosphate Receptor Modulators Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 26. Sphingosine 1 Phosphate Receptor Modulators Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 27. Mixed Polymers Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 28. Mixed Polymers Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 29. Mixed Polymers Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 30. Mixed Polymers Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 31. Mixed Polymers Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 32. NF-κB Inhibitor Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 33. NF-κB Inhibitor Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 34. NF-κB Inhibitor Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 35. NF-κB Inhibitor Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 36. NF-κB Inhibitor Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 37. Pyrimidine Synthesis Inhibitor Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 38. Pyrimidine Synthesis Inhibitor Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 39. Pyrimidine Synthesis Inhibitor Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 40. Pyrimidine Synthesis Inhibitor Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 41. Pyrimidine Synthesis Inhibitor Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 42. Monoclonal Antibodies Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 43. Monoclonal Antibodies Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 44. Monoclonal Antibodies Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 45. Monoclonal Antibodies Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 46. Monoclonal Antibodies Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 47. Adrenocorticotropic Hormone Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 48. Adrenocorticotropic Hormone Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 49. Adrenocorticotropic Hormone Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 50. Adrenocorticotropic Hormone Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 51. Adrenocorticotropic Hormone Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 52. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 53. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 54. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 55. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 56. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 57. Multiple Sclerosis Drugs Market Forecast By Disease Type 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 58. Multiple Sclerosis Drugs Market Forecast By Disease Type 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 59. Multiple Sclerosis Drugs Market Forecast By Disease Type 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 60. Multiple Sclerosis Drugs Market Forecast By Disease Type 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 61. Multiple Sclerosis Drugs Market Forecast By Disease Type 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 62. Relapsing-remitting MS (RRMS) Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 63. Relapsing-remitting MS (RRMS) Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 64. Relapsing-remitting MS (RRMS) Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 65. Relapsing-remitting MS (RRMS) Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 66. Relapsing-remitting MS (RRMS) Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 67. Primary-progressive MS (PPMS) Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 68. Primary-progressive MS (PPMS) Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 69. Primary-progressive MS (PPMS) Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 70. Primary-progressive MS (PPMS) Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 71. Primary-progressive MS (PPMS) Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 72. Secondary-progressive MS (SPMS) Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 73. Secondary-progressive MS (SPMS) Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 74. Secondary-progressive MS (SPMS) Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 75. Secondary-progressive MS (SPMS) Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 76. Secondary-progressive MS (SPMS) Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 77. Progressive-relapsing MS (PRMS) Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 78. Progressive-relapsing MS (PRMS) Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 79. Progressive-relapsing MS (PRMS) Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 80. Progressive-relapsing MS (PRMS) Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 81. Progressive-relapsing MS (PRMS) Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 82. Multiple Sclerosis Drugs Market Forecast By Patient Demographics 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 83. Multiple Sclerosis Drugs Market Forecast By Patient Demographics 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 84. Multiple Sclerosis Drugs Market Forecast By Patient Demographics 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 85. Multiple Sclerosis Drugs Market Forecast By Patient Demographics 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 86. Multiple Sclerosis Drugs Market Forecast By Patient Demographics 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 87. Geriatric Patient Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 88. Geriatric Patient Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 89. Geriatric Patient Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 90. Geriatric Patient Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 91. Geriatric Patient Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 92. Adult Patient Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 93. Adult Patient Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 94. Adult Patient Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 95. Adult Patient Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 96. Adult Patient Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 97. Pediatric Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 98. Pediatric Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 99. Pediatric Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 100. Pediatric Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 101. Pediatric Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 102. Multiple Sclerosis Drugs Market Forecast By Route of Administration 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 103. Multiple Sclerosis Drugs Market Forecast By Route of Administration 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 104. Multiple Sclerosis Drugs Market Forecast By Route of Administration 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 105. Multiple Sclerosis Drugs Market Forecast By Route of Administration 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 106. Multiple Sclerosis Drugs Market Forecast By Route of Administration 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 107. Oral Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 108. Oral Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 109. Oral Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 110. Oral Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 111. Oral Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 112. Parenteral Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 113. Parenteral Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 114. Parenteral Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 115. Parenteral Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 116. Parenteral Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 117. Multiple Sclerosis Drugs Market Forecast By Drug Type 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 118. Multiple Sclerosis Drugs Market Forecast By Drug Type 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 119. Multiple Sclerosis Drugs Market Forecast By Drug Type 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 120. Multiple Sclerosis Drugs Market Forecast By Drug Type 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 121. Multiple Sclerosis Drugs Market Forecast By Drug Type 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 122. Generic Drugs Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 123. Generic Drugs Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 124. Generic Drugs Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 125. Generic Drugs Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 126. Generic Drugs Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 127. Branded Drugs Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 128. Branded Drugs Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 129. Branded Drugs Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 130. Branded Drugs Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 131. Branded Drugs Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 132. Multiple Sclerosis Drugs Market Forecast By End-User 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 133. Multiple Sclerosis Drugs Market Forecast By End-User 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 134. Multiple Sclerosis Drugs Market Forecast By End-User 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 135. Multiple Sclerosis Drugs Market Forecast By End-User 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 136. Multiple Sclerosis Drugs Market Forecast By End-User 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 137. Hospitals Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 138. Hospitals Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 139. Hospitals Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 140. Hospitals Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 141. Hospitals Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 142. Homecare Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 143. Homecare Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 144. Homecare Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 145. Homecare Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 146. Homecare Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 147. Specialty Clinics Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 148. Specialty Clinics Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 149. Specialty Clinics Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 150. Specialty Clinics Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 151. Specialty Clinics Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 152. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 153. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 154. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 155. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 156. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 157. Multiple Sclerosis Drugs Market Forecast By Distribution Channel 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 158. Multiple Sclerosis Drugs Market Forecast By Distribution Channel 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 159. Multiple Sclerosis Drugs Market Forecast By Distribution Channel 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 160. Multiple Sclerosis Drugs Market Forecast By Distribution Channel 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 161. Multiple Sclerosis Drugs Market Forecast By Distribution Channel 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 162. Hospital Pharmacy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 163. Hospital Pharmacy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 164. Hospital Pharmacy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 165. Hospital Pharmacy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 166. Hospital Pharmacy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 167. Retail Pharmacy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 168. Retail Pharmacy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 169. Retail Pharmacy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 170. Retail Pharmacy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 171. Retail Pharmacy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 172. Online Pharmacies Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 173. Online Pharmacies Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 174. Online Pharmacies Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 175. Online Pharmacies Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 176. Online Pharmacies Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 177. North America Multiple Sclerosis Drugs Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 178. North America Multiple Sclerosis Drugs Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 179. North America Multiple Sclerosis Drugs Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 180. North America Multiple Sclerosis Drugs Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 181. North America Multiple Sclerosis Drugs Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 182. North America Multiple Sclerosis Drugs Market Forecast By Disease Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 183. North America Multiple Sclerosis Drugs Market Forecast By Disease Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 184. North America Multiple Sclerosis Drugs Market Forecast By Disease Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 185. North America Multiple Sclerosis Drugs Market Forecast By Disease Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 186. North America Multiple Sclerosis Drugs Market Forecast By Disease Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 187. North America Multiple Sclerosis Drugs Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 188. North America Multiple Sclerosis Drugs Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 189. North America Multiple Sclerosis Drugs Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 190. North America Multiple Sclerosis Drugs Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 191. North America Multiple Sclerosis Drugs Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 192. North America Multiple Sclerosis Drugs Market Forecast By Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 193. North America Multiple Sclerosis Drugs Market Forecast By Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 194. North America Multiple Sclerosis Drugs Market Forecast By Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 195. North America Multiple Sclerosis Drugs Market Forecast By Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 196. North America Multiple Sclerosis Drugs Market Forecast By Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 197. North America Multiple Sclerosis Drugs Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 198. North America Multiple Sclerosis Drugs Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 199. North America Multiple Sclerosis Drugs Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 200. North America Multiple Sclerosis Drugs Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 201. North America Multiple Sclerosis Drugs Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 202. North America Multiple Sclerosis Drugs Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 203. North America Multiple Sclerosis Drugs Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 204. North America Multiple Sclerosis Drugs Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 205. North America Multiple Sclerosis Drugs Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 206. North America Multiple Sclerosis Drugs Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 207. North America Multiple Sclerosis Drugs Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 208. North America Multiple Sclerosis Drugs Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 209. North America Multiple Sclerosis Drugs Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 210. North America Multiple Sclerosis Drugs Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 211. North America Multiple Sclerosis Drugs Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 212. North America Multiple Sclerosis Drugs Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 213. North America Multiple Sclerosis Drugs Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 214. North America Multiple Sclerosis Drugs Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 215. North America Multiple Sclerosis Drugs Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 216. North America Multiple Sclerosis Drugs Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 217. US Multiple Sclerosis Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 218. US Multiple Sclerosis Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 219. US Multiple Sclerosis Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 220. US Multiple Sclerosis Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 221. US Multiple Sclerosis Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 222. Canada Multiple Sclerosis Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 223. Canada Multiple Sclerosis Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 224. Canada Multiple Sclerosis Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 225. Canada Multiple Sclerosis Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 226. Canada Multiple Sclerosis Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 227. Europe Multiple Sclerosis Drugs Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (Before COVID) Table 82.
Figure 228. Europe Multiple Sclerosis Drugs Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 229. Europe Multiple Sclerosis Drugs Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 230. Europe Multiple Sclerosis Drugs Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 231. Europe Multiple Sclerosis Drugs Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 232. Europe Multiple Sclerosis Drugs Market Forecast By Disease Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 233. Europe Multiple Sclerosis Drugs Market Forecast By Disease Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 234. Europe Multiple Sclerosis Drugs Market Forecast By Disease Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 235. Europe Multiple Sclerosis Drugs Market Forecast By Disease Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 236. Europe Multiple Sclerosis Drugs Market Forecast By Disease Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 237. Europe Multiple Sclerosis Drugs Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 238. Europe Multiple Sclerosis Drugs Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 239. Europe Multiple Sclerosis Drugs Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 240. Europe Multiple Sclerosis Drugs Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 241. Europe Multiple Sclerosis Drugs Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 242. Europe Multiple Sclerosis Drugs Market Forecast By Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 243. Europe Multiple Sclerosis Drugs Market Forecast By Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 244. Europe Multiple Sclerosis Drugs Market Forecast By Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 245. Europe Multiple Sclerosis Drugs Market Forecast By Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 246. Europe Multiple Sclerosis Drugs Market Forecast By Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 247. Europe Multiple Sclerosis Drugs Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 248. Europe Multiple Sclerosis Drugs Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 249. Europe Multiple Sclerosis Drugs Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 250. Europe Multiple Sclerosis Drugs Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 251. Europe Multiple Sclerosis Drugs Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 252. Europe Multiple Sclerosis Drugs Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 253. Europe Multiple Sclerosis Drugs Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 254. Europe Multiple Sclerosis Drugs Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 255. Europe Multiple Sclerosis Drugs Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 256. Europe Multiple Sclerosis Drugs Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 257. Europe Multiple Sclerosis Drugs Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 258. Europe Multiple Sclerosis Drugs Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 259. Europe Multiple Sclerosis Drugs Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 260. Europe Multiple Sclerosis Drugs Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 261. Europe Multiple Sclerosis Drugs Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 262. Europe Multiple Sclerosis Drugs Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 263. Europe Multiple Sclerosis Drugs Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 264. Europe Multiple Sclerosis Drugs Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 265. Europe Multiple Sclerosis Drugs Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 266. UK Multiple Sclerosis Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 267. UK Multiple Sclerosis Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 268. UK Multiple Sclerosis Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 269. UK Multiple Sclerosis Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 270. UK Multiple Sclerosis Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 271. Germany Multiple Sclerosis Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 272. Germany Multiple Sclerosis Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 273. Germany Multiple Sclerosis Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 274. Germany Multiple Sclerosis Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 275. Germany Multiple Sclerosis Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 276. France Multiple Sclerosis Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 277. France Multiple Sclerosis Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 278. France Multiple Sclerosis Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 279. France Multiple Sclerosis Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 280. France Multiple Sclerosis Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 281. Rest of Europe Multiple Sclerosis Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 282. Rest of Europe Multiple Sclerosis Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 283. Rest of Europe Multiple Sclerosis Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 284. Rest of Europe Multiple Sclerosis Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 285. Rest of Europe Multiple Sclerosis Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 286. Asia Pacific Multiple Sclerosis Drugs Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 287. Asia Pacific Multiple Sclerosis Drugs Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 288. Asia Pacific Multiple Sclerosis Drugs Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 289. Asia Pacific Multiple Sclerosis Drugs Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 290. Asia Pacific Multiple Sclerosis Drugs Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 291. Asia Pacific Multiple Sclerosis Drugs Market Forecast By Disease Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 292. Asia Pacific Multiple Sclerosis Drugs Market Forecast By Disease Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 293. Asia Pacific Multiple Sclerosis Drugs Market Forecast By Disease Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 294. Asia Pacific Multiple Sclerosis Drugs Market Forecast By Disease Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 295. Asia Pacific Multiple Sclerosis Drugs Market Forecast By Disease Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 296. Asia Pacific Multiple Sclerosis Drugs Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 297. Asia Pacific Multiple Sclerosis Drugs Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 298. Asia Pacific Multiple Sclerosis Drugs Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 299. Asia Pacific Multiple Sclerosis Drugs Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 300. Asia Pacific Multiple Sclerosis Drugs Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 301. Asia Pacific Multiple Sclerosis Drugs Market Forecast By Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 302. Asia Pacific Multiple Sclerosis Drugs Market Forecast By Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 303. Asia Pacific Multiple Sclerosis Drugs Market Forecast By Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 304. Asia Pacific Multiple Sclerosis Drugs Market Forecast By Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 305. Asia Pacific Multiple Sclerosis Drugs Market Forecast By Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 306. Asia Pacific Multiple Sclerosis Drugs Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 307. Asia Pacific Multiple Sclerosis Drugs Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 308. Asia Pacific Multiple Sclerosis Drugs Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 309. Asia Pacific Multiple Sclerosis Drugs Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 310. Asia Pacific Multiple Sclerosis Drugs Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 311. Asia Pacific Multiple Sclerosis Drugs Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 312. Asia Pacific Multiple Sclerosis Drugs Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 313. Asia Pacific Multiple Sclerosis Drugs Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 314. Asia Pacific Multiple Sclerosis Drugs Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 315. Asia Pacific Multiple Sclerosis Drugs Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 316. Asia Pacific Multiple Sclerosis Drugs Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 317. Asia Pacific Multiple Sclerosis Drugs Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 318. Asia Pacific Multiple Sclerosis Drugs Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 319. Asia Pacific Multiple Sclerosis Drugs Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 320. Asia Pacific Multiple Sclerosis Drugs Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 321. Asia Pacific Multiple Sclerosis Drugs Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 322. Asia Pacific Multiple Sclerosis Drugs Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 323. Asia Pacific Multiple Sclerosis Drugs Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 324. Asia Pacific Multiple Sclerosis Drugs Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 325. Asia Pacific Multiple Sclerosis Drugs Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 326. China Multiple Sclerosis Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 327. China Multiple Sclerosis Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 328. China Multiple Sclerosis Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 329. China Multiple Sclerosis Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 330. China Multiple Sclerosis Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 331. India Multiple Sclerosis Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 332. India Multiple Sclerosis Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 333. India Multiple Sclerosis Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 334. India Multiple Sclerosis Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 335. India Multiple Sclerosis Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 336. Japan Multiple Sclerosis Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 337. Japan Multiple Sclerosis Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 338. Japan Multiple Sclerosis Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 339. Japan Multiple Sclerosis Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 340. Japan Multiple Sclerosis Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 341. RoAPAC Multiple Sclerosis Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 342. RoAPAC Multiple Sclerosis Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 343. RoAPAC Multiple Sclerosis Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 344. RoAPAC Multiple Sclerosis Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 345. RoAPAC Multiple Sclerosis Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 346. Middle East Multiple Sclerosis Drugs Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 347. Middle East Multiple Sclerosis Drugs Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 348. Middle East Multiple Sclerosis Drugs Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 349. Middle East Multiple Sclerosis Drugs Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 350. Middle East Multiple Sclerosis Drugs Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 351. Middle East Multiple Sclerosis Drugs Market Forecast By Disease Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 352. Middle East Multiple Sclerosis Drugs Market Forecast By Disease Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 353. Middle East Multiple Sclerosis Drugs Market Forecast By Disease Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 354. Middle East Multiple Sclerosis Drugs Market Forecast By Disease Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 355. Middle East Multiple Sclerosis Drugs Market Forecast By Disease Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 356. Middle East Multiple Sclerosis Drugs Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 357. Middle East Multiple Sclerosis Drugs Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 358. Middle East Multiple Sclerosis Drugs Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 359. Middle East Multiple Sclerosis Drugs Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 360. Middle East Multiple Sclerosis Drugs Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 361. Middle East Multiple Sclerosis Drugs Market Forecast By Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 362. Middle East Multiple Sclerosis Drugs Market Forecast By Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 363. Middle East Multiple Sclerosis Drugs Market Forecast By Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 364. Middle East Multiple Sclerosis Drugs Market Forecast By Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 365. Middle East Multiple Sclerosis Drugs Market Forecast By Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 366. Middle East Multiple Sclerosis Drugs Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 367. Middle East Multiple Sclerosis Drugs Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 368. Middle East Multiple Sclerosis Drugs Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 369. Middle East Multiple Sclerosis Drugs Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 370. Middle East Multiple Sclerosis Drugs Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 371. Middle East Multiple Sclerosis Drugs Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 372. Middle East Multiple Sclerosis Drugs Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 373. Middle East Multiple Sclerosis Drugs Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 374. Middle East Multiple Sclerosis Drugs Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 375. Middle East Multiple Sclerosis Drugs Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 376. Middle East Multiple Sclerosis Drugs Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 377. Middle East Multiple Sclerosis Drugs Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 378. Middle East Multiple Sclerosis Drugs Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 379. Middle East Multiple Sclerosis Drugs Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 380. Middle East Multiple Sclerosis Drugs Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 381. Latin America Multiple Sclerosis Drugs Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 382. Latin America Multiple Sclerosis Drugs Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 383. Latin America Multiple Sclerosis Drugs Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 384. Latin America Multiple Sclerosis Drugs Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 385. Latin America Multiple Sclerosis Drugs Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 386. Latin America Multiple Sclerosis Drugs Market Forecast By Disease Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 387. Latin America Multiple Sclerosis Drugs Market Forecast By Disease Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 388. Latin America Multiple Sclerosis Drugs Market Forecast By Disease Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 389. Latin America Multiple Sclerosis Drugs Market Forecast By Disease Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 390. Latin America Multiple Sclerosis Drugs Market Forecast By Disease Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 391. Latin America Multiple Sclerosis Drugs Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 392. Latin America Multiple Sclerosis Drugs Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 393. Latin America Multiple Sclerosis Drugs Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 394. Latin America Multiple Sclerosis Drugs Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 395. Latin America Multiple Sclerosis Drugs Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 396. Latin America Multiple Sclerosis Drugs Market Forecast By Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 397. Latin America Multiple Sclerosis Drugs Market Forecast By Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 398. Latin America Multiple Sclerosis Drugs Market Forecast By Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 399. Latin America Multiple Sclerosis Drugs Market Forecast By Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 400. Latin America Multiple Sclerosis Drugs Market Forecast By Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 401. Latin America Multiple Sclerosis Drugs Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 402. Latin America Multiple Sclerosis Drugs Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 403. Latin America Multiple Sclerosis Drugs Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 404. Latin America Multiple Sclerosis Drugs Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 405. Latin America Multiple Sclerosis Drugs Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 406. Latin America Multiple Sclerosis Drugs Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 407. Latin America Multiple Sclerosis Drugs Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 408. Latin America Multiple Sclerosis Drugs Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 409. Latin America Multiple Sclerosis Drugs Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 410. Latin America Multiple Sclerosis Drugs Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 411. Latin America Multiple Sclerosis Drugs Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 412. Latin America Multiple Sclerosis Drugs Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 413. Latin America Multiple Sclerosis Drugs Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 414. Latin America Multiple Sclerosis Drugs Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 415. Latin America Multiple Sclerosis Drugs Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 416. Africa Multiple Sclerosis Drugs Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 417. Africa Multiple Sclerosis Drugs Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 418. Africa Multiple Sclerosis Drugs Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 419. Africa Multiple Sclerosis Drugs Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 420. Africa Multiple Sclerosis Drugs Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 421. Africa Multiple Sclerosis Drugs Market Forecast By Disease Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 422. Africa Multiple Sclerosis Drugs Market Forecast By Disease Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 423. Africa Multiple Sclerosis Drugs Market Forecast By Disease Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 424. Africa Multiple Sclerosis Drugs Market Forecast By Disease Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 425. Africa Multiple Sclerosis Drugs Market Forecast By Disease Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 426. Africa Multiple Sclerosis Drugs Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 427. Africa Multiple Sclerosis Drugs Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 428. Africa Multiple Sclerosis Drugs Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 429. Africa Multiple Sclerosis Drugs Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 430. Africa Multiple Sclerosis Drugs Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 431. Africa Multiple Sclerosis Drugs Market Forecast By Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 432. Africa Multiple Sclerosis Drugs Market Forecast By Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 433. Africa Multiple Sclerosis Drugs Market Forecast By Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 434. Africa Multiple Sclerosis Drugs Market Forecast By Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 435. Africa Multiple Sclerosis Drugs Market Forecast By Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 436. Africa Multiple Sclerosis Drugs Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 437. Africa Multiple Sclerosis Drugs Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 438. Africa Multiple Sclerosis Drugs Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 439. Africa Multiple Sclerosis Drugs Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 440. Africa Multiple Sclerosis Drugs Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 441. Africa Multiple Sclerosis Drugs Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 442. Africa Multiple Sclerosis Drugs Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 443. Africa Multiple Sclerosis Drugs Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 444. Africa Multiple Sclerosis Drugs Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 445. Africa Multiple Sclerosis Drugs Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 446. Africa Multiple Sclerosis Drugs Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 447. Africa Multiple Sclerosis Drugs Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 448. Africa Multiple Sclerosis Drugs Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 449. Africa Multiple Sclerosis Drugs Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 450. Africa Multiple Sclerosis Drugs Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 451. Porter’s Five Force Analysis
Companies Mentioned
1. AbbVie
2. Achaogen
3. Actavis
4. Actelion
5. Affinium Pharmaceutical
6. AiCuris GmbH & Co. KG
7. Alcon
8. Alkem Laboratories
9. Allergan
10. Allied Pharma
11. Apotex
12. APP Pharmaceuticals
13. Aptalis Pharma
14. Aquapharm Biodiscovery
15. Cempra Pharmaceuticals
16. Cipla
17. Claris Lifesciences
18. Cornerstone Biopharma
19. Cornerstone Therapeutics
20. Corona Remedies
21. Eli Lilly
22. Gate Pharma
23. Gilead Sciences
24. GlaxoSmithKline (GSK)
25. Glenmark
26. GlycoVaxyn
27. Hetero
28. Hikma Farmaceutica
29. Hi-Tech Pharma
30. Hospira
31. Macleod Pharmaceuticals
32. Microlabs
33. Nalneva
34. Novartis
35. Novexel
36. Paratek Pharmaceuticals
37. Pfizer
38. Ranbaxy
39. Roche
40. Sagent Pharmaceuticals
41. Sandoz
42. Sanofi
43. Sequella
44. Shanghai MengKe Pharmaceuticals
45. Shionogi
46. SHIONOGI Co., Ltd.
47. Shire
48. Sidmak Labs
49. Solitaire Pharmacia
50. Specialised Therapeutics Australia
1.1. Introduction
1.2. Why You Should Read This Report
1.3. Key Questions Answered By This Analytical Report
1.4. Who is This Report For?
1.5. Methodology
1.6. Frequently Asked Questions (FAQ)
1.7. Associated Visiongain Reports
1.8. About Visiongain
2. Introduction to the Multiple Sclerosis Drugs Market
2.1. Multiple Sclerosis Drugs Market Definition
2.2. Application Submarkets Definitions
2.3. Component Submarkets Definitions
2.4. Condition Submarkets Definitions
3. Multiple Sclerosis Drugs Market Overview
3.1. Global Multiple Sclerosis Drugs Market Size and Forecast By Region
3.2. Global Multiple Sclerosis Drugs Market Share By Region
3.3. Market Dynamics
3.3.1. Market Drivers
3.3.1.1. Increasing prevalence of multiple sclerosis
3.3.1.2. Increasing research and development for multiple sclerosis drugs
3.3.1.3. Increasing geriatric population around the world
3.3.1.4. Increasing investment in multiple sclerosis drugs market
3.3.2. Market Restraints
3.3.2.1. Stringent regulation associated with product development
3.3.2.2. High cost of development
3.3.3. Opportunities
3.3.3.1. Increasing strategic initiatives in multiple sclerosis drugs
3.3.3.2. Growing regulatory approval for multiple sclerosis drugs
3.3.4. Challenges
3.3.4.1. Changes in export & import policies in developed nations
3.3.4.2. Side effects associated with the multiple sclerosis drugs
3.3.5. SWOT Analysis
3.3.5.1. Strengths
3.3.5.1.1. Strength 1
3.3.5.1.2. Strength 2
3.3.5.1.3. Strength 3
3.3.5.2. Weaknesses
3.3.5.2.1. Weakness 1
3.3.5.2.2. Weakness 2
3.3.5.2.3. Weakness 3
3.3.5.3. Opportunities
3.3.5.3.1. Opportunity 1
3.3.5.3.2. Opportunity 2
3.3.5.3.3. Opportunity 3
3.3.5.4. Threats
3.3.5.4.1. Threat 1
3.3.5.4.2. Threat 2
3.3.5.4.3. Threat 3
3.3.6. Porter’s Five Forces Analysis
3.3.6.1. Competitive Rivalry
3.3.6.2. Supplier Power
3.3.6.3. Buyer Power
3.3.6.4. Threat of Substitution
3.3.6.5. Threat of New Entry
4. Global Multiple Sclerosis Drugs Market Analysis and Forecast 2021-2031, By Drug Class (Pre COVID and V, U, W and L COVID Recovery Scenarios)
4.1. Market Overview
4.1.1. Corticosteroids
4.1.1.1. Corticosteroids market size and forecast, 2021-2031 (USD Million)
4.1.2. Interferon Beta
4.1.2.1. Interferon Beta market size and forecast, 2021-2031 (USD Million)
4.1.3. Sphingosine 1 Phosphate Receptor Modulators
4.1.3.1. Sphingosine 1 Phosphate Receptor Modulators market size and forecast, 2021-2031 (USD Million)
4.1.4. Mixed Polymers
4.1.4.1. Mixed Polymers market size and forecast, 2021-2031 (USD Million)
4.1.5. NF-κB Inhibitor
4.1.5.1. NF-κB Inhibitor market size and forecast, 2021-2031 (USD Million)
4.1.6. Pyrimidine Synthesis Inhibitor
4.1.6.1. Pyrimidine Synthesis Inhibitor market size and forecast, 2021-2031 (USD Million)
4.1.7. Monoclonal Antibodies
4.1.7.1. Monoclonal Antibodies market size and forecast, 2021-2031 (USD Million)
4.1.8. Corticosteroids
4.1.8.1. Corticosteroids market size and forecast, 2021-2031 (USD Million)
4.1.9. Adrenocorticotropic Hormone
4.1.9.1. Adrenocorticotropic hormone market size and forecast, 2021-2031 (USD Million)
4.1.10. Others
4.1.10.1. Others market size and forecast, 2021-2031 (USD Million)
5. Global Multiple Sclerosis Drugs Market Analysis and Forecast, 2021-2031 By Disease Type (Pre COVID and V, U, W and L COVID Recovery Scenarios)
5.1. Market Overview
5.1.1. Relapsing-remitting MS (RRMS)
5.1.1.1. Relapsing-remitting MS (RRMS) market size and forecast, 2021-2031 (USD Million)
5.1.2. Primary-progressive MS (PPMS)
5.1.2.1. Primary-progressive MS (PPMS) market size and forecast, 2021-2031 (USD Million)
5.1.3. Secondary-progressive MS (SPMS)
5.1.3.1. Secondary-progressive MS (SPMS) market size and forecast, 2021-2031 (USD Million)
5.1.4. Progressive-relapsing MS (PRMS)
5.1.4.1. Progressive-relapsing MS (PRMS) market size and forecast, 2021-2031 (USD Million)
6. Global Multiple Sclerosis Drugs Market Analysis and Forecast, 2021-2031 By Patient Demographics (Pre COVID and V, U, W and L COVID Recovery Scenarios)
6.1. Market Overview
6.1.1. Geriatric Patient
6.1.1.1. Geriatric Patient market size and forecast, 2021-2031 (USD Million)
6.1.2. Adult Patient
6.1.2.1. Adult Patient market size and forecast, 2021-2031 (USD Million)
6.1.3. Pediatric
6.1.3.1. Pediatric market size and forecast, 2021-2031 (USD Million)
7. Global Multiple Sclerosis Drugs Market Analysis and Forecast, 2021-2031 By Drug Type (Pre COVID and V, U, W and L COVID Recovery Scenarios)
7.1. Market Overview
7.1.1. Generic Drugs
7.1.1.1. Generic Drugs market size and forecast, 2021-2031 (USD Million)
7.1.2. Branded Drugs
7.1.2.1. Branded Drugs market size and forecast, 2021-2031 (USD Million)
8. Global Multiple Sclerosis Drugs Market Analysis and Forecast, 2021-2031 By Route of Administration (Pre COVID and V, U, W and L COVID Recovery Scenarios)
8.1. Market Overview
8.1.1. Oral
8.1.1.1. Oral market size and forecast, 2021-2031 (USD Million)
8.1.2. Parenteral
8.1.2.1. Parenteral market size and forecast, 2021-2031 (USD Million)
9. Global Multiple Sclerosis Drugs Market Analysis and Forecast, 2021-2031 By End-User (Pre COVID and V, U, W and L COVID Recovery Scenarios)
9.1. Market Overview
9.1.1. Hospitals
9.1.1.1. Hospitals market size and forecast, 2021-2031 (USD Million)
9.1.2. Homecare
9.1.2.1. Homecare market size and forecast, 2021-2031 (USD Million)
9.1.3. Specialty Clinics
9.1.3.1. Specialty Clinics market size and forecast, 2021-2031 (USD Million)
9.1.4. Others
9.1.4.1. Others market size and forecast, 2021-2031 (USD Million)
10. Global Multiple Sclerosis Drugs Market Analysis and Forecast, 2021-2031 By Distribution Channel (Pre COVID and V, U, W and L COVID Recovery Scenarios)
10.1. Market Overview
10.1.1. Hospitals Pharmacy
10.1.1.1. Hospitals Pharmacy market size and forecast, 2021-2031 (USD Million)
10.1.2. Retail Pharmacy
10.1.2.1. Retail Pharmacy market size and forecast, 2021-2031 (USD Million)
10.1.3. Online Pharmacies
10.1.3.1. Online Pharmacies market size and forecast, 2021-2031 (USD Million)
11. North America Multiple Sclerosis Drugs Market Analysis and Forecast, 2021-2031 Pre COVID and V, U, W and L COVID Recovery Scenarios)
11.1. Market Overview
11.2. North America Multiple Sclerosis Drugs Market Size and Forecast By Drug Class
11.2.1.1. XX Driving/Opportunity Factor
11.2.1.2. XX Driving/Opportunity Factor
11.3. North America Multiple Sclerosis Drugs Market Size and Forecast By Disease Type
11.3.1.1. XX Driving/Opportunity Factor
11.3.1.2. XX Driving/Opportunity Factor
11.4. North America Multiple Sclerosis Drugs Market Size and Forecast By Drug Type
11.4.1.1. XX Driving/Opportunity Factor
11.4.1.2. XX Driving/Opportunity Factor
11.5. North America Multiple Sclerosis Drugs Market Size and Forecast By Patient Demographics
11.5.1.1. XX Driving/Opportunity Factor
11.5.1.2. XX Driving/Opportunity Factor
11.6. North America Multiple Sclerosis Drugs Market Size and Forecast By Route of Administration
11.6.1.1. XX Driving/Opportunity Factor
11.6.1.2. XX Driving/Opportunity Factor
11.7. North America Multiple Sclerosis Drugs Market Size and Forecast By End-User
11.7.1.1. XX Driving/Opportunity Factor
11.7.1.2. XX Driving/Opportunity Factor
11.8. North America Multiple Sclerosis Drugs Market Size and Forecast By Distribution Channel
11.8.1.1. XX Driving/Opportunity Factor
11.8.1.2. XX Driving/Opportunity Factor
11.9. U.S. Multiple Sclerosis Drugs Market
11.9.1.1. XX Driving/Opportunity Factor
11.9.1.2. XX Driving/Opportunity Factor
11.10. Canada Multiple Sclerosis Drugs Market
11.10.1.1. XX Driving/Opportunity Factor
11.10.1.2. XX Driving/Opportunity Factor
12. Europe Multiple Sclerosis Drugs Market Analysis and Forecast, 2021-2031 (Pre COVID and V, U, W and L COVID Recovery Scenarios)
12.1. Market Overview
12.2. Europe Multiple Sclerosis Drugs Market Size and Forecast By Drug Class
12.2.1.1. XX Driving/Opportunity Factor
12.2.1.2. XX Driving/Opportunity Factor
12.3. Europe Multiple Sclerosis Drugs Market Size and Forecast By Disease Type
12.3.1.1. XX Driving/Opportunity Factor
12.3.1.2. XX Driving/Opportunity Factor
12.4. Europe Multiple Sclerosis Drugs Market Size and Forecast By Patient Demographics
12.4.1.1. XX Driving/Opportunity Factor
12.4.1.2. XX Driving/Opportunity Factor
12.5. Europe Multiple Sclerosis Drugs Market Size and Forecast By Drug Type
12.5.1.1. XX Driving/Opportunity Factor
12.5.1.2. XX Driving/Opportunity Factor
12.6. Europe Multiple Sclerosis Drugs Market Size and Forecast By Route of Administration
12.6.1.1. XX Driving/Opportunity Factor
12.6.1.2. XX Driving/Opportunity Factor
12.7. Europe Multiple Sclerosis Drugs Market Size and Forecast By End-User
12.7.1.1. XX Driving/Opportunity Factor
12.7.1.2. XX Driving/Opportunity Factor
12.8. Europe Multiple Sclerosis Drugs Market Size and Forecast By Distribution Channel
12.8.1.1. XX Driving/Opportunity Factor
12.8.1.2. XX Driving/Opportunity Factor
12.9. UK Multiple Sclerosis Drugs Market
12.9.1.1. XX Driving/Opportunity Factor
12.9.1.2. XX Driving/Opportunity Factor
12.10. Germany Multiple Sclerosis Drugs Market
12.10.1.1. XX Driving/Opportunity Factor
12.10.1.2. XX Driving/Opportunity Factor
12.11. France Multiple Sclerosis Drugs Market
12.11.1.1. XX Driving/Opportunity Factor
12.11.1.2. XX Driving/Opportunity Factor
12.12. Rest of Europe Multiple Sclerosis Drugs Market
12.12.1.1. XX Driving/Opportunity Factor
12.12.1.2. XX Driving/Opportunity Factor
13. Asia Pacific Multiple Sclerosis Drugs Market Analysis and Forecast, 2021-2031 (Pre COVID and V, U, W and L COVID Recovery Scenarios)
13.1. Market Overview
13.2. Asia-Pacific Multiple Sclerosis Drugs Market Size and Forecast By Drug Class
13.2.1.1. XX Driving/Opportunity Factor
13.2.1.2. XX Driving/Opportunity Factor
13.3. Asia-Pacific Multiple Sclerosis Drugs Market Size and Forecast By Disease Type
13.3.1.1. XX Driving/Opportunity Factor
13.3.1.2. XX Driving/Opportunity Factor
13.4. Asia-Pacific Multiple Sclerosis Drugs Market Size and Forecast By Patient Demographics
13.4.1.1. XX Driving/Opportunity Factor
13.4.1.2. XX Driving/Opportunity Factor
13.5. Asia-Pacific Multiple Sclerosis Drugs Market Size and Forecast By Drug Type
13.5.1.1. XX Driving/Opportunity Factor
13.5.1.2. XX Driving/Opportunity Factor
13.6. Asia-Pacific Multiple Sclerosis Drugs Market Size and Forecast By Route of Administration
13.6.1.1. XX Driving/Opportunity Factor
13.6.1.2. XX Driving/Opportunity Factor
13.7. Asia-Pacific Multiple Sclerosis Drugs Market Size and Forecast By End-User
13.7.1.1. XX Driving/Opportunity Factor
13.7.1.2. XX Driving/Opportunity Factor
13.8. Asia-Pacific Multiple Sclerosis Drugs Market Size and Forecast By Distribution Channel
13.8.1.1. XX Driving/Opportunity Factor
13.8.1.2. XX Driving/Opportunity Factor
13.9. China Multiple Sclerosis Drugs Market
13.9.1.1. XX Driving/Opportunity Factor
13.9.1.2. XX Driving/Opportunity Factor
13.10. India Multiple Sclerosis Drugs Market
13.10.1.1. XX Driving/Opportunity Factor
13.10.1.2. XX Driving/Opportunity Factor
13.11. Japan Multiple Sclerosis Drugs Market
13.11.1.1. XX Driving/Opportunity Factor
13.11.1.2. XX Driving/Opportunity Factor
13.12. Rest of Asia Pacific Multiple Sclerosis Drugs Market
13.12.1.1. XX Driving/Opportunity Factor
13.12.1.2. XX Driving/Opportunity Factor
14. Latin America Multiple Sclerosis Drugs Market Analysis and Forecast, 2021-2031 (Pre COVID and V, U, W and L COVID Recovery Scenarios)
14.1. Market Overview
14.2. Latin America Multiple Sclerosis Drugs Market Size and Forecast By Drug Class
14.2.1.1. XX Driving/Opportunity Factor
14.2.1.2. XX Driving/Opportunity Factor
14.3. Latin America Multiple Sclerosis Drugs Market Size and Forecast By Disease Type
14.3.1.1. XX Driving/Opportunity Factor
14.3.1.2. XX Driving/Opportunity Factor
14.4. Latin America Multiple Sclerosis Drugs Market Size and Forecast By Patient Demographics
14.4.1.1. XX Driving/Opportunity Factor
14.4.1.2. XX Driving/Opportunity Factor
14.5. Latin America Multiple Sclerosis Drugs Market Size and Forecast By Drug Type
14.5.1.1. XX Driving/Opportunity Factor
14.5.1.2. XX Driving/Opportunity Factor
14.6. Latin America Multiple Sclerosis Drugs Market Size and Forecast By Route of Administration
14.6.1.1. XX Driving/Opportunity Factor
14.6.1.2. XX Driving/Opportunity Factor
14.7. Latin America Multiple Sclerosis Drugs Market Size and Forecast By End-User
14.7.1.1. XX Driving/Opportunity Factor
14.7.1.2. XX Driving/Opportunity Factor
14.8. Latin America Multiple Sclerosis Drugs Market Size and Forecast By Distribution Channel
14.9. Brazil Multiple Sclerosis Drugs Market
14.9.1.1. XX Driving/Opportunity Factor
14.9.1.2. XX Driving/Opportunity Factor
14.10. Mexico Multiple Sclerosis Drugs Market
14.10.1.1. XX Driving/Opportunity Factor
14.10.1.2. XX Driving/Opportunity Factor
14.11. Rest of Latin America Multiple Sclerosis Drugs Market
14.11.1.1. XX Driving/Opportunity Factor
14.11.1.2. XX Driving/Opportunity Factor
15. MEA Multiple Sclerosis Drugs Market Analysis and Forecast, 2021-2031 (Pre COVID and V, U, W and L COVID Recovery Scenarios)
15.1. Market Overview
15.2. MEA Multiple Sclerosis Drugs Market Size and Forecast By Drug Class
15.2.1.1. XX Driving/Opportunity Factor
15.2.1.2. XX Driving/Opportunity Factor
15.3. MEA Multiple Sclerosis Drugs Market Size and Forecast By Disease Type
15.3.1.1. XX Driving/Opportunity Factor
15.3.1.2. XX Driving/Opportunity Factor
15.4. MEA Multiple Sclerosis Drugs Market Size and Forecast By Patient Demographics
15.4.1.1. XX Driving/Opportunity Factor
15.4.1.2. XX Driving/Opportunity Factor
15.5. MEA Multiple Sclerosis Drugs Market Size and Forecast By Drug Type
15.5.1.1. XX Driving/Opportunity Factor
15.5.1.2. XX Driving/Opportunity Factor
15.6. MEA Multiple Sclerosis Drugs Market Size and Forecast By Route of Administration
15.6.1.1. XX Driving/Opportunity Factor
15.6.1.2. XX Driving/Opportunity Factor
15.7. MEA Multiple Sclerosis Drugs Market Size and Forecast By End-User
15.7.1.1. XX Driving/Opportunity Factor
15.7.1.2. XX Driving/Opportunity Factor
15.8. MEA Multiple Sclerosis Drugs Market Size and Forecast By Distribution Channel
15.8.1.1. XX Driving/Opportunity Factor
15.8.1.2. XX Driving/Opportunity Factor
15.9. GCC Multiple Sclerosis Drugs Market
15.9.1.1. XX Driving/Opportunity Factor
15.9.1.2. XX Driving/Opportunity Factor
15.10. South Africa Multiple Sclerosis Drugs Market
15.10.1.1. XX Driving/Opportunity Factor
15.10.1.2. XX Driving/Opportunity Factor
15.11. Rest of MEA Multiple Sclerosis Drugs Market
15.11.1.1. XX Driving/Opportunity Factor
15.11.1.2. XX Driving/Opportunity Factor
16. Companies in the Multiple Sclerosis Drugs Market
16.1. Shire Plc
16.1.1. Company Snapshot
16.1.2. Company Overview
16.1.3. Financial Performance (2015-2019)
16.1.3.1. Net Revenue
16.1.3.2. Gross Profit
16.1.3.3. Geographical Revenue, 2019
16.1.4. Product Offerings
16.1.5. Recent Initiatives (2017-2019)
16.2. BioCryst Pharmaceuticals, Inc.
16.2.1. Company Snapshot
16.2.2. Company Overview
16.2.3. Financial Performance (2015-2019)
16.2.3.1. Net Revenue
16.2.3.2. Gross Profit
16.2.3.3. Geographical Revenue, 2019
16.2.4. Product Offerings
16.2.5. Recent Initiatives (2017-2019)
16.3. Ionis Pharmaceuticals, Inc.
16.3.1. Company Snapshot
16.3.2. Company Overview
16.3.3. Financial Performance (2015-2019)
16.3.3.1. Net Revenue
16.3.3.2. Gross Profit
16.3.3.3. Geographical Revenue, 2019
16.3.4. Product Offerings
16.3.5. Recent Initiatives (2017-2019)
16.4. Pharming Group N.V.
16.4.1. Company Snapshot
16.4.2. Company Overview
16.4.3. Financial Performance (2015-2019)
16.4.3.1. Net Revenue
16.4.3.2. Gross Profit
16.4.3.3. Geographical Revenue, 2019
16.4.4. Product Offerings
16.4.5. Recent Initiatives (2017-2019)
16.5. CSL Limited
16.5.1. Company Snapshot
16.5.2. Company Overview
16.5.3. Financial Performance (2015-2019)
16.5.3.1. Net Revenue
16.5.3.2. Gross Profit
16.5.3.3. Geographical Revenue, 2019
16.5.4. Product Offerings
16.5.5. Recent Initiatives (2017-2019)
16.6. Attune Pharmaceuticals, Inc.
16.6.1. Company Snapshot
16.6.2. Company Overview
16.6.3. Financial Performance (2015-2019)
16.6.3.1. Net Revenue
16.6.3.2. Gross Profit
16.6.3.3. Geographical Revenue, 2019
16.6.4. Product Offerings
16.6.5. Recent Initiatives (2017-2019)
16.7. Adverum Biotechnologies, Inc.
16.7.1. Company Snapshot
16.7.2. Company Overview
16.7.3. Financial Performance (2015-2019)
16.7.3.1. Net Revenue
16.7.3.2. Gross Profit
16.7.3.3. Geographical Revenue, 2019
16.7.4. Product Offerings
16.7.5. Recent Initiatives (2017-2019)
16.8. KalVista Pharmaceuticals, Inc.
16.8.1. Company Snapshot
16.8.2. Company Overview
16.8.3. Financial Performance (2015-2019)
16.8.3.1. Net Revenue
16.8.3.2. Gross Profit
16.8.3.3. Geographical Revenue, 2019
16.8.4. Product Offerings
16.8.5. Recent Initiatives (2017-2019)
16.9. Takeda Pharmaceutical Company Limited
16.9.1. Company Snapshot
16.9.2. Company Overview
16.9.3. Financial Performance (2015-2019)
16.9.3.1. Net Revenue
16.9.3.2. Gross Profit
16.9.3.3. Geographical Revenue, 2019
16.9.4. Product Offerings
16.9.5. Recent Initiatives (2017-2019)
16.10. Pharming Healthcare, Inc.
16.10.1. Company Snapshot
16.10.2. Company Overview
16.10.3. Financial Performance (2015-2019)
16.10.3.1. Net Revenue
16.10.3.2. Gross Profit
16.10.3.3. Geographical Revenue, 2019
16.10.4. Product Offerings
16.10.5. Recent Initiatives (2017-2019)
16.11. Other Notable Players
17. Conclusion
18. Glossary
Associated Visiongain Reports
Visiongain Report Sales Order Form
Appendix A
About Visiongain
Appendix B
Visiongain report evaluation form
LIST OF TABLES
Table 1. Multiple Sclerosis Drugs Market Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 2. Multiple Sclerosis Drugs Market Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 3. Multiple Sclerosis Drugs Market Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 4. Multiple Sclerosis Drugs Market Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 5. Multiple Sclerosis Drugs Market Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 6. Multiple Sclerosis Drugs Market Drivers & Restraints 2021
Table 7. Multiple Sclerosis Drugs Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 8. Multiple Sclerosis Drugs Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 9. Multiple Sclerosis Drugs Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 10. Multiple Sclerosis Drugs Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 11. Multiple Sclerosis Drugs Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 12. Corticosteroids Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 13. Corticosteroids Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 14. Corticosteroids Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 15. Corticosteroids Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 16. Corticosteroids Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 17. Interferon Beta Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 18. Interferon Beta Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 19. Interferon Beta Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 20. Interferon Beta Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 21. Interferon Beta Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 22. Sphingosine 1 Phosphate Receptor Modulators Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 23. Sphingosine 1 Phosphate Receptor Modulators Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 24. Sphingosine 1 Phosphate Receptor Modulators Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 25. Sphingosine 1 Phosphate Receptor Modulators Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 26. Sphingosine 1 Phosphate Receptor Modulators Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 27. Mixed Polymers Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 28. Mixed Polymers Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 29. Mixed Polymers Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 30. Mixed Polymers Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 31. Mixed Polymers Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 32. NF-κB Inhibitor Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 33. NF-κB Inhibitor Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 34. NF-κB Inhibitor Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 35. NF-κB Inhibitor Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 36. NF-κB Inhibitor Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 37. Pyrimidine Synthesis Inhibitor Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 38. Pyrimidine Synthesis Inhibitor Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 39. Pyrimidine Synthesis Inhibitor Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 40. Pyrimidine Synthesis Inhibitor Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 41. Pyrimidine Synthesis Inhibitor Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 42. Monoclonal Antibodies Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 43. Monoclonal Antibodies Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 44. Monoclonal Antibodies Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 45. Monoclonal Antibodies Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 46. Monoclonal Antibodies Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 47. Adrenocorticotropic Hormone Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 48. Adrenocorticotropic Hormone Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 49. Adrenocorticotropic Hormone Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 50. Adrenocorticotropic Hormone Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 51. Adrenocorticotropic Hormone Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 52. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 53. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 54. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 55. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 56. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 57. Multiple Sclerosis Drugs Market Forecast By Disease Type 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 58. Multiple Sclerosis Drugs Market Forecast By Disease Type 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 59. Multiple Sclerosis Drugs Market Forecast By Disease Type 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 60. Multiple Sclerosis Drugs Market Forecast By Disease Type 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 61. Multiple Sclerosis Drugs Market Forecast By Disease Type 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 62. Relapsing-remitting MS (RRMS) Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 63. Relapsing-remitting MS (RRMS) Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 64. Relapsing-remitting MS (RRMS) Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 65. Relapsing-remitting MS (RRMS) Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 66. Relapsing-remitting MS (RRMS) Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 67. Primary-progressive MS (PPMS) Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 68. Primary-progressive MS (PPMS) Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 69. Primary-progressive MS (PPMS) Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 70. Primary-progressive MS (PPMS) Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 71. Primary-progressive MS (PPMS) Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 72. Secondary-progressive MS (SPMS) Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 73. Secondary-progressive MS (SPMS) Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 74. Secondary-progressive MS (SPMS) Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 75. Secondary-progressive MS (SPMS) Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 76. Secondary-progressive MS (SPMS) Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 77. Progressive-relapsing MS (PRMS) Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 78. Progressive-relapsing MS (PRMS) Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 79. Progressive-relapsing MS (PRMS) Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 80. Progressive-relapsing MS (PRMS) Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 81. Progressive-relapsing MS (PRMS) Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 82. Multiple Sclerosis Drugs Market Forecast By Patient Demographics 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 83. Multiple Sclerosis Drugs Market Forecast By Patient Demographics 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 84. Multiple Sclerosis Drugs Market Forecast By Patient Demographics 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 85. Multiple Sclerosis Drugs Market Forecast By Patient Demographics 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 86. Multiple Sclerosis Drugs Market Forecast By Patient Demographics 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 87. Geriatric Patient Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 88. Geriatric Patient Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 89. Geriatric Patient Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 90. Geriatric Patient Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 91. Geriatric Patient Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 92. Adult Patient Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 93. Adult Patient Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 94. Adult Patient Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 95. Adult Patient Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 96. Adult Patient Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 97. Pediatric Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 98. Pediatric Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 99. Pediatric Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 100. Pediatric Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 101. Pediatric Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 102. Multiple Sclerosis Drugs Market Forecast By Route of Administration 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 103. Multiple Sclerosis Drugs Market Forecast By Route of Administration 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 104. Multiple Sclerosis Drugs Market Forecast By Route of Administration 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 105. Multiple Sclerosis Drugs Market Forecast By Route of Administration 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 106. Multiple Sclerosis Drugs Market Forecast By Route of Administration 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 107. Oral Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 108. Oral Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 109. Oral Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 110. Oral Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 111. Oral Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 112. Parenteral Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 113. Parenteral Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 114. Parenteral Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 115. Parenteral Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 116. Parenteral Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 117. Multiple Sclerosis Drugs Market Forecast By Drug Type 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 118. Multiple Sclerosis Drugs Market Forecast By Drug Type 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 119. Multiple Sclerosis Drugs Market Forecast By Drug Type 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 120. Multiple Sclerosis Drugs Market Forecast By Drug Type 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 121. Multiple Sclerosis Drugs Market Forecast By Drug Type 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 122. Generic Drugs Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 123. Generic Drugs Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 124. Generic Drugs Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 125. Generic Drugs Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 126. Generic Drugs Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 127. Branded Drugs Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 128. Branded Drugs Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 129. Branded Drugs Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 130. Branded Drugs Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 131. Branded Drugs Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 132. Multiple Sclerosis Drugs Market Forecast By End-User 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 133. Multiple Sclerosis Drugs Market Forecast By End-User 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 134. Multiple Sclerosis Drugs Market Forecast By End-User 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 135. Multiple Sclerosis Drugs Market Forecast By End-User 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 136. Multiple Sclerosis Drugs Market Forecast By End-User 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 137. Hospitals Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 138. Hospitals Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 139. Hospitals Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 140. Hospitals Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 141. Hospitals Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 142. Homecare Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 143. Homecare Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 144. Homecare Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 145. Homecare Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 146. Homecare Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 147. Specialty Clinics Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 148. Specialty Clinics Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 149. Specialty Clinics Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 150. Specialty Clinics Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 151. Specialty Clinics Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 152. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 153. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 154. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 155. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 156. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 157. Multiple Sclerosis Drugs Market Forecast By Distribution Channel 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 158. Multiple Sclerosis Drugs Market Forecast By Distribution Channel 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 159. Multiple Sclerosis Drugs Market Forecast By Distribution Channel 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 160. Multiple Sclerosis Drugs Market Forecast By Distribution Channel 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 161. Multiple Sclerosis Drugs Market Forecast By Distribution Channel 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 162. Hospital Pharmacy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 163. Hospital Pharmacy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 164. Hospital Pharmacy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 165. Hospital Pharmacy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 166. Hospital Pharmacy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 167. Retail Pharmacy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 168. Retail Pharmacy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 169. Retail Pharmacy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 170. Retail Pharmacy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 171. Retail Pharmacy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 172. Online Pharmacies Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 173. Online Pharmacies Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 174. Online Pharmacies Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 175. Online Pharmacies Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 176. Online Pharmacies Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 177. North America Multiple Sclerosis Drugs Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 178. North America Multiple Sclerosis Drugs Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 179. North America Multiple Sclerosis Drugs Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 180. North America Multiple Sclerosis Drugs Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 181. North America Multiple Sclerosis Drugs Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 182. North America Multiple Sclerosis Drugs Market Forecast By Disease Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 183. North America Multiple Sclerosis Drugs Market Forecast By Disease Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 184. North America Multiple Sclerosis Drugs Market Forecast By Disease Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 185. North America Multiple Sclerosis Drugs Market Forecast By Disease Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 186. North America Multiple Sclerosis Drugs Market Forecast By Disease Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 187. North America Multiple Sclerosis Drugs Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 188. North America Multiple Sclerosis Drugs Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 189. North America Multiple Sclerosis Drugs Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 190. North America Multiple Sclerosis Drugs Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 191. North America Multiple Sclerosis Drugs Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 192. North America Multiple Sclerosis Drugs Market Forecast By Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 193. North America Multiple Sclerosis Drugs Market Forecast By Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 194. North America Multiple Sclerosis Drugs Market Forecast By Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 195. North America Multiple Sclerosis Drugs Market Forecast By Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 196. North America Multiple Sclerosis Drugs Market Forecast By Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 197. North America Multiple Sclerosis Drugs Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 198. North America Multiple Sclerosis Drugs Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 199. North America Multiple Sclerosis Drugs Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 200. North America Multiple Sclerosis Drugs Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 201. North America Multiple Sclerosis Drugs Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 202. North America Multiple Sclerosis Drugs Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 203. North America Multiple Sclerosis Drugs Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 204. North America Multiple Sclerosis Drugs Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 205. North America Multiple Sclerosis Drugs Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 206. North America Multiple Sclerosis Drugs Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 207. North America Multiple Sclerosis Drugs Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 208. North America Multiple Sclerosis Drugs Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 209. North America Multiple Sclerosis Drugs Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 210. North America Multiple Sclerosis Drugs Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 211. North America Multiple Sclerosis Drugs Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 212. North America Multiple Sclerosis Drugs Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 213. North America Multiple Sclerosis Drugs Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 214. North America Multiple Sclerosis Drugs Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 215. North America Multiple Sclerosis Drugs Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 216. North America Multiple Sclerosis Drugs Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 217. US Multiple Sclerosis Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 218. US Multiple Sclerosis Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 219. US Multiple Sclerosis Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 220. US Multiple Sclerosis Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 221. US Multiple Sclerosis Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 222. Canada Multiple Sclerosis Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 223. Canada Multiple Sclerosis Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 224. Canada Multiple Sclerosis Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 225. Canada Multiple Sclerosis Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 226. Canada Multiple Sclerosis Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 227. Europe Multiple Sclerosis Drugs Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (Before COVID) Table 82.
Table 228. Europe Multiple Sclerosis Drugs Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 229. Europe Multiple Sclerosis Drugs Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 230. Europe Multiple Sclerosis Drugs Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 231. Europe Multiple Sclerosis Drugs Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 232. Europe Multiple Sclerosis Drugs Market Forecast By Disease Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 233. Europe Multiple Sclerosis Drugs Market Forecast By Disease Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 234. Europe Multiple Sclerosis Drugs Market Forecast By Disease Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 235. Europe Multiple Sclerosis Drugs Market Forecast By Disease Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 236. Europe Multiple Sclerosis Drugs Market Forecast By Disease Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 237. Europe Multiple Sclerosis Drugs Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 238. Europe Multiple Sclerosis Drugs Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 239. Europe Multiple Sclerosis Drugs Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 240. Europe Multiple Sclerosis Drugs Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 241. Europe Multiple Sclerosis Drugs Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 242. Europe Multiple Sclerosis Drugs Market Forecast By Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 243. Europe Multiple Sclerosis Drugs Market Forecast By Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 244. Europe Multiple Sclerosis Drugs Market Forecast By Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 245. Europe Multiple Sclerosis Drugs Market Forecast By Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 246. Europe Multiple Sclerosis Drugs Market Forecast By Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 247. Europe Multiple Sclerosis Drugs Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 248. Europe Multiple Sclerosis Drugs Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 249. Europe Multiple Sclerosis Drugs Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 250. Europe Multiple Sclerosis Drugs Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 251. Europe Multiple Sclerosis Drugs Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 252. Europe Multiple Sclerosis Drugs Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 253. Europe Multiple Sclerosis Drugs Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 254. Europe Multiple Sclerosis Drugs Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 255. Europe Multiple Sclerosis Drugs Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 256. Europe Multiple Sclerosis Drugs Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 257. Europe Multiple Sclerosis Drugs Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 258. Europe Multiple Sclerosis Drugs Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 259. Europe Multiple Sclerosis Drugs Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 260. Europe Multiple Sclerosis Drugs Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 261. Europe Multiple Sclerosis Drugs Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 262. Europe Multiple Sclerosis Drugs Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 263. Europe Multiple Sclerosis Drugs Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 264. Europe Multiple Sclerosis Drugs Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 265. Europe Multiple Sclerosis Drugs Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 266. UK Multiple Sclerosis Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 267. UK Multiple Sclerosis Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 268. UK Multiple Sclerosis Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 269. UK Multiple Sclerosis Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 270. UK Multiple Sclerosis Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 271. Germany Multiple Sclerosis Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 272. Germany Multiple Sclerosis Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 273. Germany Multiple Sclerosis Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 274. Germany Multiple Sclerosis Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 275. Germany Multiple Sclerosis Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 276. France Multiple Sclerosis Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 277. France Multiple Sclerosis Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 278. France Multiple Sclerosis Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 279. France Multiple Sclerosis Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 280. France Multiple Sclerosis Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 281. Rest of Europe Multiple Sclerosis Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 282. Rest of Europe Multiple Sclerosis Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 283. Rest of Europe Multiple Sclerosis Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 284. Rest of Europe Multiple Sclerosis Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 285. Rest of Europe Multiple Sclerosis Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 286. Asia Pacific Multiple Sclerosis Drugs Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 287. Asia Pacific Multiple Sclerosis Drugs Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 288. Asia Pacific Multiple Sclerosis Drugs Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 289. Asia Pacific Multiple Sclerosis Drugs Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 290. Asia Pacific Multiple Sclerosis Drugs Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 291. Asia Pacific Multiple Sclerosis Drugs Market Forecast By Disease Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 292. Asia Pacific Multiple Sclerosis Drugs Market Forecast By Disease Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 293. Asia Pacific Multiple Sclerosis Drugs Market Forecast By Disease Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 294. Asia Pacific Multiple Sclerosis Drugs Market Forecast By Disease Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 295. Asia Pacific Multiple Sclerosis Drugs Market Forecast By Disease Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 296. Asia Pacific Multiple Sclerosis Drugs Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 297. Asia Pacific Multiple Sclerosis Drugs Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 298. Asia Pacific Multiple Sclerosis Drugs Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 299. Asia Pacific Multiple Sclerosis Drugs Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 300. Asia Pacific Multiple Sclerosis Drugs Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 301. Asia Pacific Multiple Sclerosis Drugs Market Forecast By Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 302. Asia Pacific Multiple Sclerosis Drugs Market Forecast By Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 303. Asia Pacific Multiple Sclerosis Drugs Market Forecast By Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 304. Asia Pacific Multiple Sclerosis Drugs Market Forecast By Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 305. Asia Pacific Multiple Sclerosis Drugs Market Forecast By Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 306. Asia Pacific Multiple Sclerosis Drugs Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 307. Asia Pacific Multiple Sclerosis Drugs Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 308. Asia Pacific Multiple Sclerosis Drugs Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 309. Asia Pacific Multiple Sclerosis Drugs Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 310. Asia Pacific Multiple Sclerosis Drugs Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 311. Asia Pacific Multiple Sclerosis Drugs Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 312. Asia Pacific Multiple Sclerosis Drugs Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 313. Asia Pacific Multiple Sclerosis Drugs Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 314. Asia Pacific Multiple Sclerosis Drugs Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 315. Asia Pacific Multiple Sclerosis Drugs Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 316. Asia Pacific Multiple Sclerosis Drugs Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 317. Asia Pacific Multiple Sclerosis Drugs Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 318. Asia Pacific Multiple Sclerosis Drugs Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 319. Asia Pacific Multiple Sclerosis Drugs Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 320. Asia Pacific Multiple Sclerosis Drugs Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 321. Asia Pacific Multiple Sclerosis Drugs Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 322. Asia Pacific Multiple Sclerosis Drugs Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 323. Asia Pacific Multiple Sclerosis Drugs Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 324. Asia Pacific Multiple Sclerosis Drugs Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 325. Asia Pacific Multiple Sclerosis Drugs Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 326. China Multiple Sclerosis Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 327. China Multiple Sclerosis Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 328. China Multiple Sclerosis Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 329. China Multiple Sclerosis Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 330. China Multiple Sclerosis Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 331. India Multiple Sclerosis Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 332. India Multiple Sclerosis Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 333. India Multiple Sclerosis Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 334. India Multiple Sclerosis Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 335. India Multiple Sclerosis Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 336. Japan Multiple Sclerosis Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 337. Japan Multiple Sclerosis Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 338. Japan Multiple Sclerosis Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 339. Japan Multiple Sclerosis Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 340. Japan Multiple Sclerosis Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 341. RoAPAC Multiple Sclerosis Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 342. RoAPAC Multiple Sclerosis Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 343. RoAPAC Multiple Sclerosis Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 344. RoAPAC Multiple Sclerosis Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 345. RoAPAC Multiple Sclerosis Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 346. Middle East Multiple Sclerosis Drugs Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 347. Middle East Multiple Sclerosis Drugs Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 348. Middle East Multiple Sclerosis Drugs Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 349. Middle East Multiple Sclerosis Drugs Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 350. Middle East Multiple Sclerosis Drugs Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 351. Middle East Multiple Sclerosis Drugs Market Forecast By Disease Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 352. Middle East Multiple Sclerosis Drugs Market Forecast By Disease Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 353. Middle East Multiple Sclerosis Drugs Market Forecast By Disease Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 354. Middle East Multiple Sclerosis Drugs Market Forecast By Disease Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 355. Middle East Multiple Sclerosis Drugs Market Forecast By Disease Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 356. Middle East Multiple Sclerosis Drugs Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 357. Middle East Multiple Sclerosis Drugs Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 358. Middle East Multiple Sclerosis Drugs Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 359. Middle East Multiple Sclerosis Drugs Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 360. Middle East Multiple Sclerosis Drugs Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 361. Middle East Multiple Sclerosis Drugs Market Forecast By Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 362. Middle East Multiple Sclerosis Drugs Market Forecast By Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 363. Middle East Multiple Sclerosis Drugs Market Forecast By Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 364. Middle East Multiple Sclerosis Drugs Market Forecast By Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 365. Middle East Multiple Sclerosis Drugs Market Forecast By Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 366. Middle East Multiple Sclerosis Drugs Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 367. Middle East Multiple Sclerosis Drugs Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 368. Middle East Multiple Sclerosis Drugs Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 369. Middle East Multiple Sclerosis Drugs Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 370. Middle East Multiple Sclerosis Drugs Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 371. Middle East Multiple Sclerosis Drugs Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 372. Middle East Multiple Sclerosis Drugs Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 373. Middle East Multiple Sclerosis Drugs Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 374. Middle East Multiple Sclerosis Drugs Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 375. Middle East Multiple Sclerosis Drugs Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 376. Middle East Multiple Sclerosis Drugs Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 377. Middle East Multiple Sclerosis Drugs Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 378. Middle East Multiple Sclerosis Drugs Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 379. Middle East Multiple Sclerosis Drugs Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 380. Middle East Multiple Sclerosis Drugs Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 381. Latin America Multiple Sclerosis Drugs Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 382. Latin America Multiple Sclerosis Drugs Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 383. Latin America Multiple Sclerosis Drugs Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 384. Latin America Multiple Sclerosis Drugs Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 385. Latin America Multiple Sclerosis Drugs Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 386. Latin America Multiple Sclerosis Drugs Market Forecast By Disease Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 387. Latin America Multiple Sclerosis Drugs Market Forecast By Disease Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 388. Latin America Multiple Sclerosis Drugs Market Forecast By Disease Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 389. Latin America Multiple Sclerosis Drugs Market Forecast By Disease Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 390. Latin America Multiple Sclerosis Drugs Market Forecast By Disease Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 391. Latin America Multiple Sclerosis Drugs Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 392. Latin America Multiple Sclerosis Drugs Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 393. Latin America Multiple Sclerosis Drugs Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 394. Latin America Multiple Sclerosis Drugs Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 395. Latin America Multiple Sclerosis Drugs Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 396. Latin America Multiple Sclerosis Drugs Market Forecast By Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 397. Latin America Multiple Sclerosis Drugs Market Forecast By Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 398. Latin America Multiple Sclerosis Drugs Market Forecast By Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 399. Latin America Multiple Sclerosis Drugs Market Forecast By Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 400. Latin America Multiple Sclerosis Drugs Market Forecast By Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 401. Latin America Multiple Sclerosis Drugs Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 402. Latin America Multiple Sclerosis Drugs Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 403. Latin America Multiple Sclerosis Drugs Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 404. Latin America Multiple Sclerosis Drugs Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 405. Latin America Multiple Sclerosis Drugs Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 406. Latin America Multiple Sclerosis Drugs Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 407. Latin America Multiple Sclerosis Drugs Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 408. Latin America Multiple Sclerosis Drugs Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 409. Latin America Multiple Sclerosis Drugs Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 410. Latin America Multiple Sclerosis Drugs Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 411. Latin America Multiple Sclerosis Drugs Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 412. Latin America Multiple Sclerosis Drugs Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 413. Latin America Multiple Sclerosis Drugs Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 414. Latin America Multiple Sclerosis Drugs Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 415. Latin America Multiple Sclerosis Drugs Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 416. Africa Multiple Sclerosis Drugs Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 417. Africa Multiple Sclerosis Drugs Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 418. Africa Multiple Sclerosis Drugs Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 419. Africa Multiple Sclerosis Drugs Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 420. Africa Multiple Sclerosis Drugs Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 421. Africa Multiple Sclerosis Drugs Market Forecast By Disease Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 422. Africa Multiple Sclerosis Drugs Market Forecast By Disease Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 423. Africa Multiple Sclerosis Drugs Market Forecast By Disease Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 424. Africa Multiple Sclerosis Drugs Market Forecast By Disease Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 425. Africa Multiple Sclerosis Drugs Market Forecast By Disease Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 426. Africa Multiple Sclerosis Drugs Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 427. Africa Multiple Sclerosis Drugs Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 428. Africa Multiple Sclerosis Drugs Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 429. Africa Multiple Sclerosis Drugs Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 430. Africa Multiple Sclerosis Drugs Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 431. Africa Multiple Sclerosis Drugs Market Forecast By Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 432. Africa Multiple Sclerosis Drugs Market Forecast By Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 433. Africa Multiple Sclerosis Drugs Market Forecast By Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 434. Africa Multiple Sclerosis Drugs Market Forecast By Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 435. Africa Multiple Sclerosis Drugs Market Forecast By Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 436. Africa Multiple Sclerosis Drugs Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 437. Africa Multiple Sclerosis Drugs Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 438. Africa Multiple Sclerosis Drugs Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 439. Africa Multiple Sclerosis Drugs Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 440. Africa Multiple Sclerosis Drugs Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 441. Africa Multiple Sclerosis Drugs Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 442. Africa Multiple Sclerosis Drugs Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 443. Africa Multiple Sclerosis Drugs Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 444. Africa Multiple Sclerosis Drugs Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 445. Africa Multiple Sclerosis Drugs Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 446. Africa Multiple Sclerosis Drugs Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 447. Africa Multiple Sclerosis Drugs Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 448. Africa Multiple Sclerosis Drugs Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 449. Africa Multiple Sclerosis Drugs Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 450. Africa Multiple Sclerosis Drugs Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 451. Leading 10 Multiple Sclerosis Drugs Companies (Ranking, Company, Latest Total Company Sales US$M*, HQ)
Table 452. Shire PlcProfile 2019 (CEO, HQ, Founded, Website)
Table 453. Shire Plc Multiple Sclerosis Drugs Product Offering (Segment, Product Offerings)
Table 454. BioCryst Pharmaceuticals, Inc. Profile 2019 (CEO, HQ, Founded, Website)
Table 455. BioCryst Pharmaceuticals, Inc. Multiple Sclerosis Drugs Product Offering (Segment, Product Offerings)
Table 456. Ionis Pharmaceuticals, Inc. Profile 2019 (CEO, HQ, Founded, Website)
Table 457. Ionis Pharmaceuticals, Inc..Multiple Sclerosis Drugs Product Offering (Segment, Product Offerings)
Table 458. Pharming Group N.V. Profile 2019 (CEO, HQ, Founded, Website)
Table 459. Pharming Group N.V. Multiple Sclerosis Drugs Product Offering (Segment, Product Offerings)
Table 460. CSL Limited Profile 2019 (CEO, HQ, Founded, Website)
Table 461. CSL Limited Multiple Sclerosis Drugs Product Offering (Segment, Product Offerings)
Table 462. Attune Pharmaceuticals, Inc. Profile 2019 (CEO, HQ, Founded, Website)
Table 463. Attune Pharmaceuticals, Inc. Multiple Sclerosis Drugs Product Offering (Segment, Product Offerings)
Table 464. Adverum Biotechnologies, Inc. Profile 2019 (CEO, HQ, Founded, Website)
Table 465. Adverum Biotechnologies, Inc. Multiple Sclerosis Drugs Product Offering (Segment, Product Offerings)
Table 466. KalVista Pharmaceuticals, Inc. Profile 2019 (CEO, HQ, Founded, Website)
Table 467. KalVista Pharmaceuticals, Inc. Multiple Sclerosis Drugs Product Offering (Segment, Product Offerings)
Table 468. Takeda Pharmaceutical Company Limited Profile 2019 (CEO, HQ, Founded, Website)
Table 469. Takeda Pharmaceutical Company Limited Multiple Sclerosis Drugs Product Offering (Segment, Product Offerings)
Table 470. Pharming Healthcare, Inc. Corporation Profile 2019 (CEO, HQ, Founded, Website)
Table 471. Pharming Healthcare, Inc. Multiple Sclerosis Drugs Product Offering (Segment, Product Offerings)
Table 472. Other Companies Involved in the Multiple Sclerosis Drugs Market 2021 (Company, Location)
LIST OF FIGURES
Figure 1. Multiple Sclerosis Drugs Market Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 2. Multiple Sclerosis Drugs Market Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 3. Multiple Sclerosis Drugs Market Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 4. Multiple Sclerosis Drugs Market Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 5. Multiple Sclerosis Drugs Market Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 6. Multiple Sclerosis Drugs Market Drivers & Restraints 2021
Figure 7. Multiple Sclerosis Drugs Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 8. Multiple Sclerosis Drugs Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 9. Multiple Sclerosis Drugs Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 10. Multiple Sclerosis Drugs Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 11. Multiple Sclerosis Drugs Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 12. Corticosteroids Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 13. Corticosteroids Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 14. Corticosteroids Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 15. Corticosteroids Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 16. Corticosteroids Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 17. Interferon Beta Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 18. Interferon Beta Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 19. Interferon Beta Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 20. Interferon Beta Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 21. Interferon Beta Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 22. Sphingosine 1 Phosphate Receptor Modulators Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 23. Sphingosine 1 Phosphate Receptor Modulators Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 24. Sphingosine 1 Phosphate Receptor Modulators Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 25. Sphingosine 1 Phosphate Receptor Modulators Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 26. Sphingosine 1 Phosphate Receptor Modulators Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 27. Mixed Polymers Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 28. Mixed Polymers Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 29. Mixed Polymers Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 30. Mixed Polymers Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 31. Mixed Polymers Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 32. NF-κB Inhibitor Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 33. NF-κB Inhibitor Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 34. NF-κB Inhibitor Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 35. NF-κB Inhibitor Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 36. NF-κB Inhibitor Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 37. Pyrimidine Synthesis Inhibitor Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 38. Pyrimidine Synthesis Inhibitor Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 39. Pyrimidine Synthesis Inhibitor Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 40. Pyrimidine Synthesis Inhibitor Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 41. Pyrimidine Synthesis Inhibitor Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 42. Monoclonal Antibodies Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 43. Monoclonal Antibodies Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 44. Monoclonal Antibodies Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 45. Monoclonal Antibodies Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 46. Monoclonal Antibodies Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 47. Adrenocorticotropic Hormone Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 48. Adrenocorticotropic Hormone Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 49. Adrenocorticotropic Hormone Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 50. Adrenocorticotropic Hormone Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 51. Adrenocorticotropic Hormone Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 52. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 53. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 54. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 55. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 56. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 57. Multiple Sclerosis Drugs Market Forecast By Disease Type 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 58. Multiple Sclerosis Drugs Market Forecast By Disease Type 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 59. Multiple Sclerosis Drugs Market Forecast By Disease Type 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 60. Multiple Sclerosis Drugs Market Forecast By Disease Type 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 61. Multiple Sclerosis Drugs Market Forecast By Disease Type 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 62. Relapsing-remitting MS (RRMS) Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 63. Relapsing-remitting MS (RRMS) Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 64. Relapsing-remitting MS (RRMS) Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 65. Relapsing-remitting MS (RRMS) Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 66. Relapsing-remitting MS (RRMS) Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 67. Primary-progressive MS (PPMS) Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 68. Primary-progressive MS (PPMS) Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 69. Primary-progressive MS (PPMS) Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 70. Primary-progressive MS (PPMS) Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 71. Primary-progressive MS (PPMS) Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 72. Secondary-progressive MS (SPMS) Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 73. Secondary-progressive MS (SPMS) Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 74. Secondary-progressive MS (SPMS) Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 75. Secondary-progressive MS (SPMS) Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 76. Secondary-progressive MS (SPMS) Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 77. Progressive-relapsing MS (PRMS) Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 78. Progressive-relapsing MS (PRMS) Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 79. Progressive-relapsing MS (PRMS) Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 80. Progressive-relapsing MS (PRMS) Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 81. Progressive-relapsing MS (PRMS) Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 82. Multiple Sclerosis Drugs Market Forecast By Patient Demographics 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 83. Multiple Sclerosis Drugs Market Forecast By Patient Demographics 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 84. Multiple Sclerosis Drugs Market Forecast By Patient Demographics 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 85. Multiple Sclerosis Drugs Market Forecast By Patient Demographics 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 86. Multiple Sclerosis Drugs Market Forecast By Patient Demographics 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 87. Geriatric Patient Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 88. Geriatric Patient Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 89. Geriatric Patient Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 90. Geriatric Patient Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 91. Geriatric Patient Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 92. Adult Patient Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 93. Adult Patient Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 94. Adult Patient Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 95. Adult Patient Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 96. Adult Patient Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 97. Pediatric Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 98. Pediatric Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 99. Pediatric Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 100. Pediatric Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 101. Pediatric Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 102. Multiple Sclerosis Drugs Market Forecast By Route of Administration 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 103. Multiple Sclerosis Drugs Market Forecast By Route of Administration 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 104. Multiple Sclerosis Drugs Market Forecast By Route of Administration 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 105. Multiple Sclerosis Drugs Market Forecast By Route of Administration 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 106. Multiple Sclerosis Drugs Market Forecast By Route of Administration 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 107. Oral Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 108. Oral Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 109. Oral Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 110. Oral Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 111. Oral Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 112. Parenteral Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 113. Parenteral Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 114. Parenteral Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 115. Parenteral Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 116. Parenteral Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 117. Multiple Sclerosis Drugs Market Forecast By Drug Type 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 118. Multiple Sclerosis Drugs Market Forecast By Drug Type 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 119. Multiple Sclerosis Drugs Market Forecast By Drug Type 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 120. Multiple Sclerosis Drugs Market Forecast By Drug Type 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 121. Multiple Sclerosis Drugs Market Forecast By Drug Type 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 122. Generic Drugs Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 123. Generic Drugs Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 124. Generic Drugs Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 125. Generic Drugs Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 126. Generic Drugs Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 127. Branded Drugs Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 128. Branded Drugs Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 129. Branded Drugs Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 130. Branded Drugs Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 131. Branded Drugs Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 132. Multiple Sclerosis Drugs Market Forecast By End-User 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 133. Multiple Sclerosis Drugs Market Forecast By End-User 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 134. Multiple Sclerosis Drugs Market Forecast By End-User 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 135. Multiple Sclerosis Drugs Market Forecast By End-User 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 136. Multiple Sclerosis Drugs Market Forecast By End-User 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 137. Hospitals Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 138. Hospitals Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 139. Hospitals Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 140. Hospitals Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 141. Hospitals Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 142. Homecare Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 143. Homecare Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 144. Homecare Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 145. Homecare Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 146. Homecare Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 147. Specialty Clinics Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 148. Specialty Clinics Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 149. Specialty Clinics Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 150. Specialty Clinics Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 151. Specialty Clinics Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 152. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 153. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 154. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 155. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 156. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 157. Multiple Sclerosis Drugs Market Forecast By Distribution Channel 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 158. Multiple Sclerosis Drugs Market Forecast By Distribution Channel 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 159. Multiple Sclerosis Drugs Market Forecast By Distribution Channel 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 160. Multiple Sclerosis Drugs Market Forecast By Distribution Channel 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 161. Multiple Sclerosis Drugs Market Forecast By Distribution Channel 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 162. Hospital Pharmacy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 163. Hospital Pharmacy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 164. Hospital Pharmacy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 165. Hospital Pharmacy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 166. Hospital Pharmacy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 167. Retail Pharmacy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 168. Retail Pharmacy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 169. Retail Pharmacy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 170. Retail Pharmacy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 171. Retail Pharmacy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 172. Online Pharmacies Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 173. Online Pharmacies Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 174. Online Pharmacies Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 175. Online Pharmacies Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 176. Online Pharmacies Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 177. North America Multiple Sclerosis Drugs Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 178. North America Multiple Sclerosis Drugs Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 179. North America Multiple Sclerosis Drugs Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 180. North America Multiple Sclerosis Drugs Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 181. North America Multiple Sclerosis Drugs Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 182. North America Multiple Sclerosis Drugs Market Forecast By Disease Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 183. North America Multiple Sclerosis Drugs Market Forecast By Disease Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 184. North America Multiple Sclerosis Drugs Market Forecast By Disease Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 185. North America Multiple Sclerosis Drugs Market Forecast By Disease Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 186. North America Multiple Sclerosis Drugs Market Forecast By Disease Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 187. North America Multiple Sclerosis Drugs Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 188. North America Multiple Sclerosis Drugs Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 189. North America Multiple Sclerosis Drugs Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 190. North America Multiple Sclerosis Drugs Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 191. North America Multiple Sclerosis Drugs Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 192. North America Multiple Sclerosis Drugs Market Forecast By Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 193. North America Multiple Sclerosis Drugs Market Forecast By Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 194. North America Multiple Sclerosis Drugs Market Forecast By Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 195. North America Multiple Sclerosis Drugs Market Forecast By Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 196. North America Multiple Sclerosis Drugs Market Forecast By Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 197. North America Multiple Sclerosis Drugs Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 198. North America Multiple Sclerosis Drugs Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 199. North America Multiple Sclerosis Drugs Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 200. North America Multiple Sclerosis Drugs Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 201. North America Multiple Sclerosis Drugs Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 202. North America Multiple Sclerosis Drugs Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 203. North America Multiple Sclerosis Drugs Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 204. North America Multiple Sclerosis Drugs Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 205. North America Multiple Sclerosis Drugs Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 206. North America Multiple Sclerosis Drugs Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 207. North America Multiple Sclerosis Drugs Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 208. North America Multiple Sclerosis Drugs Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 209. North America Multiple Sclerosis Drugs Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 210. North America Multiple Sclerosis Drugs Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 211. North America Multiple Sclerosis Drugs Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 212. North America Multiple Sclerosis Drugs Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 213. North America Multiple Sclerosis Drugs Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 214. North America Multiple Sclerosis Drugs Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 215. North America Multiple Sclerosis Drugs Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 216. North America Multiple Sclerosis Drugs Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 217. US Multiple Sclerosis Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 218. US Multiple Sclerosis Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 219. US Multiple Sclerosis Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 220. US Multiple Sclerosis Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 221. US Multiple Sclerosis Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 222. Canada Multiple Sclerosis Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 223. Canada Multiple Sclerosis Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 224. Canada Multiple Sclerosis Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 225. Canada Multiple Sclerosis Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 226. Canada Multiple Sclerosis Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 227. Europe Multiple Sclerosis Drugs Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (Before COVID) Table 82.
Figure 228. Europe Multiple Sclerosis Drugs Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 229. Europe Multiple Sclerosis Drugs Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 230. Europe Multiple Sclerosis Drugs Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 231. Europe Multiple Sclerosis Drugs Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 232. Europe Multiple Sclerosis Drugs Market Forecast By Disease Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 233. Europe Multiple Sclerosis Drugs Market Forecast By Disease Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 234. Europe Multiple Sclerosis Drugs Market Forecast By Disease Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 235. Europe Multiple Sclerosis Drugs Market Forecast By Disease Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 236. Europe Multiple Sclerosis Drugs Market Forecast By Disease Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 237. Europe Multiple Sclerosis Drugs Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 238. Europe Multiple Sclerosis Drugs Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 239. Europe Multiple Sclerosis Drugs Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 240. Europe Multiple Sclerosis Drugs Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 241. Europe Multiple Sclerosis Drugs Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 242. Europe Multiple Sclerosis Drugs Market Forecast By Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 243. Europe Multiple Sclerosis Drugs Market Forecast By Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 244. Europe Multiple Sclerosis Drugs Market Forecast By Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 245. Europe Multiple Sclerosis Drugs Market Forecast By Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 246. Europe Multiple Sclerosis Drugs Market Forecast By Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 247. Europe Multiple Sclerosis Drugs Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 248. Europe Multiple Sclerosis Drugs Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 249. Europe Multiple Sclerosis Drugs Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 250. Europe Multiple Sclerosis Drugs Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 251. Europe Multiple Sclerosis Drugs Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 252. Europe Multiple Sclerosis Drugs Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 253. Europe Multiple Sclerosis Drugs Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 254. Europe Multiple Sclerosis Drugs Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 255. Europe Multiple Sclerosis Drugs Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 256. Europe Multiple Sclerosis Drugs Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 257. Europe Multiple Sclerosis Drugs Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 258. Europe Multiple Sclerosis Drugs Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 259. Europe Multiple Sclerosis Drugs Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 260. Europe Multiple Sclerosis Drugs Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 261. Europe Multiple Sclerosis Drugs Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 262. Europe Multiple Sclerosis Drugs Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 263. Europe Multiple Sclerosis Drugs Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 264. Europe Multiple Sclerosis Drugs Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 265. Europe Multiple Sclerosis Drugs Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 266. UK Multiple Sclerosis Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 267. UK Multiple Sclerosis Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 268. UK Multiple Sclerosis Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 269. UK Multiple Sclerosis Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 270. UK Multiple Sclerosis Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 271. Germany Multiple Sclerosis Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 272. Germany Multiple Sclerosis Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 273. Germany Multiple Sclerosis Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 274. Germany Multiple Sclerosis Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 275. Germany Multiple Sclerosis Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 276. France Multiple Sclerosis Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 277. France Multiple Sclerosis Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 278. France Multiple Sclerosis Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 279. France Multiple Sclerosis Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 280. France Multiple Sclerosis Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 281. Rest of Europe Multiple Sclerosis Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 282. Rest of Europe Multiple Sclerosis Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 283. Rest of Europe Multiple Sclerosis Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 284. Rest of Europe Multiple Sclerosis Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 285. Rest of Europe Multiple Sclerosis Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 286. Asia Pacific Multiple Sclerosis Drugs Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 287. Asia Pacific Multiple Sclerosis Drugs Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 288. Asia Pacific Multiple Sclerosis Drugs Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 289. Asia Pacific Multiple Sclerosis Drugs Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 290. Asia Pacific Multiple Sclerosis Drugs Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 291. Asia Pacific Multiple Sclerosis Drugs Market Forecast By Disease Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 292. Asia Pacific Multiple Sclerosis Drugs Market Forecast By Disease Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 293. Asia Pacific Multiple Sclerosis Drugs Market Forecast By Disease Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 294. Asia Pacific Multiple Sclerosis Drugs Market Forecast By Disease Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 295. Asia Pacific Multiple Sclerosis Drugs Market Forecast By Disease Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 296. Asia Pacific Multiple Sclerosis Drugs Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 297. Asia Pacific Multiple Sclerosis Drugs Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 298. Asia Pacific Multiple Sclerosis Drugs Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 299. Asia Pacific Multiple Sclerosis Drugs Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 300. Asia Pacific Multiple Sclerosis Drugs Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 301. Asia Pacific Multiple Sclerosis Drugs Market Forecast By Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 302. Asia Pacific Multiple Sclerosis Drugs Market Forecast By Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 303. Asia Pacific Multiple Sclerosis Drugs Market Forecast By Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 304. Asia Pacific Multiple Sclerosis Drugs Market Forecast By Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 305. Asia Pacific Multiple Sclerosis Drugs Market Forecast By Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 306. Asia Pacific Multiple Sclerosis Drugs Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 307. Asia Pacific Multiple Sclerosis Drugs Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 308. Asia Pacific Multiple Sclerosis Drugs Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 309. Asia Pacific Multiple Sclerosis Drugs Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 310. Asia Pacific Multiple Sclerosis Drugs Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 311. Asia Pacific Multiple Sclerosis Drugs Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 312. Asia Pacific Multiple Sclerosis Drugs Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 313. Asia Pacific Multiple Sclerosis Drugs Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 314. Asia Pacific Multiple Sclerosis Drugs Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 315. Asia Pacific Multiple Sclerosis Drugs Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 316. Asia Pacific Multiple Sclerosis Drugs Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 317. Asia Pacific Multiple Sclerosis Drugs Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 318. Asia Pacific Multiple Sclerosis Drugs Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 319. Asia Pacific Multiple Sclerosis Drugs Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 320. Asia Pacific Multiple Sclerosis Drugs Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 321. Asia Pacific Multiple Sclerosis Drugs Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 322. Asia Pacific Multiple Sclerosis Drugs Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 323. Asia Pacific Multiple Sclerosis Drugs Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 324. Asia Pacific Multiple Sclerosis Drugs Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 325. Asia Pacific Multiple Sclerosis Drugs Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 326. China Multiple Sclerosis Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 327. China Multiple Sclerosis Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 328. China Multiple Sclerosis Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 329. China Multiple Sclerosis Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 330. China Multiple Sclerosis Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 331. India Multiple Sclerosis Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 332. India Multiple Sclerosis Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 333. India Multiple Sclerosis Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 334. India Multiple Sclerosis Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 335. India Multiple Sclerosis Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 336. Japan Multiple Sclerosis Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 337. Japan Multiple Sclerosis Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 338. Japan Multiple Sclerosis Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 339. Japan Multiple Sclerosis Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 340. Japan Multiple Sclerosis Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 341. RoAPAC Multiple Sclerosis Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 342. RoAPAC Multiple Sclerosis Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 343. RoAPAC Multiple Sclerosis Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 344. RoAPAC Multiple Sclerosis Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 345. RoAPAC Multiple Sclerosis Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 346. Middle East Multiple Sclerosis Drugs Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 347. Middle East Multiple Sclerosis Drugs Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 348. Middle East Multiple Sclerosis Drugs Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 349. Middle East Multiple Sclerosis Drugs Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 350. Middle East Multiple Sclerosis Drugs Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 351. Middle East Multiple Sclerosis Drugs Market Forecast By Disease Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 352. Middle East Multiple Sclerosis Drugs Market Forecast By Disease Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 353. Middle East Multiple Sclerosis Drugs Market Forecast By Disease Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 354. Middle East Multiple Sclerosis Drugs Market Forecast By Disease Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 355. Middle East Multiple Sclerosis Drugs Market Forecast By Disease Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 356. Middle East Multiple Sclerosis Drugs Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 357. Middle East Multiple Sclerosis Drugs Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 358. Middle East Multiple Sclerosis Drugs Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 359. Middle East Multiple Sclerosis Drugs Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 360. Middle East Multiple Sclerosis Drugs Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 361. Middle East Multiple Sclerosis Drugs Market Forecast By Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 362. Middle East Multiple Sclerosis Drugs Market Forecast By Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 363. Middle East Multiple Sclerosis Drugs Market Forecast By Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 364. Middle East Multiple Sclerosis Drugs Market Forecast By Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 365. Middle East Multiple Sclerosis Drugs Market Forecast By Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 366. Middle East Multiple Sclerosis Drugs Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 367. Middle East Multiple Sclerosis Drugs Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 368. Middle East Multiple Sclerosis Drugs Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 369. Middle East Multiple Sclerosis Drugs Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 370. Middle East Multiple Sclerosis Drugs Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 371. Middle East Multiple Sclerosis Drugs Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 372. Middle East Multiple Sclerosis Drugs Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 373. Middle East Multiple Sclerosis Drugs Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 374. Middle East Multiple Sclerosis Drugs Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 375. Middle East Multiple Sclerosis Drugs Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 376. Middle East Multiple Sclerosis Drugs Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 377. Middle East Multiple Sclerosis Drugs Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 378. Middle East Multiple Sclerosis Drugs Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 379. Middle East Multiple Sclerosis Drugs Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 380. Middle East Multiple Sclerosis Drugs Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 381. Latin America Multiple Sclerosis Drugs Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 382. Latin America Multiple Sclerosis Drugs Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 383. Latin America Multiple Sclerosis Drugs Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 384. Latin America Multiple Sclerosis Drugs Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 385. Latin America Multiple Sclerosis Drugs Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 386. Latin America Multiple Sclerosis Drugs Market Forecast By Disease Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 387. Latin America Multiple Sclerosis Drugs Market Forecast By Disease Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 388. Latin America Multiple Sclerosis Drugs Market Forecast By Disease Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 389. Latin America Multiple Sclerosis Drugs Market Forecast By Disease Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 390. Latin America Multiple Sclerosis Drugs Market Forecast By Disease Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 391. Latin America Multiple Sclerosis Drugs Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 392. Latin America Multiple Sclerosis Drugs Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 393. Latin America Multiple Sclerosis Drugs Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 394. Latin America Multiple Sclerosis Drugs Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 395. Latin America Multiple Sclerosis Drugs Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 396. Latin America Multiple Sclerosis Drugs Market Forecast By Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 397. Latin America Multiple Sclerosis Drugs Market Forecast By Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 398. Latin America Multiple Sclerosis Drugs Market Forecast By Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 399. Latin America Multiple Sclerosis Drugs Market Forecast By Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 400. Latin America Multiple Sclerosis Drugs Market Forecast By Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 401. Latin America Multiple Sclerosis Drugs Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 402. Latin America Multiple Sclerosis Drugs Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 403. Latin America Multiple Sclerosis Drugs Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 404. Latin America Multiple Sclerosis Drugs Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 405. Latin America Multiple Sclerosis Drugs Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 406. Latin America Multiple Sclerosis Drugs Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 407. Latin America Multiple Sclerosis Drugs Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 408. Latin America Multiple Sclerosis Drugs Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 409. Latin America Multiple Sclerosis Drugs Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 410. Latin America Multiple Sclerosis Drugs Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 411. Latin America Multiple Sclerosis Drugs Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 412. Latin America Multiple Sclerosis Drugs Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 413. Latin America Multiple Sclerosis Drugs Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 414. Latin America Multiple Sclerosis Drugs Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 415. Latin America Multiple Sclerosis Drugs Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 416. Africa Multiple Sclerosis Drugs Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 417. Africa Multiple Sclerosis Drugs Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 418. Africa Multiple Sclerosis Drugs Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 419. Africa Multiple Sclerosis Drugs Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 420. Africa Multiple Sclerosis Drugs Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 421. Africa Multiple Sclerosis Drugs Market Forecast By Disease Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 422. Africa Multiple Sclerosis Drugs Market Forecast By Disease Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 423. Africa Multiple Sclerosis Drugs Market Forecast By Disease Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 424. Africa Multiple Sclerosis Drugs Market Forecast By Disease Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 425. Africa Multiple Sclerosis Drugs Market Forecast By Disease Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 426. Africa Multiple Sclerosis Drugs Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 427. Africa Multiple Sclerosis Drugs Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 428. Africa Multiple Sclerosis Drugs Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 429. Africa Multiple Sclerosis Drugs Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 430. Africa Multiple Sclerosis Drugs Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 431. Africa Multiple Sclerosis Drugs Market Forecast By Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 432. Africa Multiple Sclerosis Drugs Market Forecast By Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 433. Africa Multiple Sclerosis Drugs Market Forecast By Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 434. Africa Multiple Sclerosis Drugs Market Forecast By Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 435. Africa Multiple Sclerosis Drugs Market Forecast By Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 436. Africa Multiple Sclerosis Drugs Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 437. Africa Multiple Sclerosis Drugs Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 438. Africa Multiple Sclerosis Drugs Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 439. Africa Multiple Sclerosis Drugs Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 440. Africa Multiple Sclerosis Drugs Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 441. Africa Multiple Sclerosis Drugs Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 442. Africa Multiple Sclerosis Drugs Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 443. Africa Multiple Sclerosis Drugs Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 444. Africa Multiple Sclerosis Drugs Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 445. Africa Multiple Sclerosis Drugs Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 446. Africa Multiple Sclerosis Drugs Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 447. Africa Multiple Sclerosis Drugs Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 448. Africa Multiple Sclerosis Drugs Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 449. Africa Multiple Sclerosis Drugs Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 450. Africa Multiple Sclerosis Drugs Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 451. Porter’s Five Force Analysis
Companies Mentioned
1. AbbVie
2. Achaogen
3. Actavis
4. Actelion
5. Affinium Pharmaceutical
6. AiCuris GmbH & Co. KG
7. Alcon
8. Alkem Laboratories
9. Allergan
10. Allied Pharma
11. Apotex
12. APP Pharmaceuticals
13. Aptalis Pharma
14. Aquapharm Biodiscovery
15. Cempra Pharmaceuticals
16. Cipla
17. Claris Lifesciences
18. Cornerstone Biopharma
19. Cornerstone Therapeutics
20. Corona Remedies
21. Eli Lilly
22. Gate Pharma
23. Gilead Sciences
24. GlaxoSmithKline (GSK)
25. Glenmark
26. GlycoVaxyn
27. Hetero
28. Hikma Farmaceutica
29. Hi-Tech Pharma
30. Hospira
31. Macleod Pharmaceuticals
32. Microlabs
33. Nalneva
34. Novartis
35. Novexel
36. Paratek Pharmaceuticals
37. Pfizer
38. Ranbaxy
39. Roche
40. Sagent Pharmaceuticals
41. Sandoz
42. Sanofi
43. Sequella
44. Shanghai MengKe Pharmaceuticals
45. Shionogi
46. SHIONOGI Co., Ltd.
47. Shire
48. Sidmak Labs
49. Solitaire Pharmacia
50. Specialised Therapeutics Australia
Companies Profiled in the Report
1. Bayer AG
2. Teva Pharmaceutical Industries Ltd.
3. Novartis AG
4. F. Hoffmann-La Roche Ltd.
5. Celgene Corporation
6. Acorda Therapeutics, Inc.
7. Sanofi
8. Actelion Pharmaceuticals (Johnson & Johnson)
9. EMD Serono (Merck KGaA)
10. AbbVie, Inc.
List of Companies Mentioned in the Report:
1. AbbVie
2. Achaogen
3. Actavis
4. Actelion
5. Affinium Pharmaceutical
6. AiCuris GmbH & Co. KG
7. Alcon
8. Alkem Laboratories
9. Allergan
10. Allied Pharma
11. Apotex
12. APP Pharmaceuticals
13. Aptalis Pharma
14. Aquapharm Biodiscovery
15. Cempra Pharmaceuticals
16. Cipla
17. Claris Lifesciences
18. Cornerstone Biopharma
19. Cornerstone Therapeutics
20. Corona Remedies
21. Eli Lilly
22. Gate Pharma
23. Gilead Sciences
24. GlaxoSmithKline (GSK)
25. Glenmark
26. GlycoVaxyn
27. Hetero
28. Hikma Farmaceutica
29. Hi-Tech Pharma
30. Hospira
31. Macleod Pharmaceuticals
32. Microlabs
33. Nalneva
34. Novartis
35. Novexel
36. Paratek Pharmaceuticals
37. Pfizer
38. Ranbaxy
39. Roche
40. Sagent Pharmaceuticals
41. Sandoz
42. Sanofi
43. Sequella
44. Shanghai MengKe Pharmaceuticals
45. Shionogi
46. SHIONOGI Co., Ltd.
47. Shire
48. Sidmak Labs
49. Solitaire Pharmacia
50. Specialised Therapeutics Australia
List of Organizations Mentioned in the Report:
1. European Medicines Agency (EMA)
2. Food and Drug Administration (FDA)
3. National Institutes of Health (NIH)
4. United Nations (UN)
5. United Nations Office on Drugs and Crime (UNODC)
6. United Nations Statistics Division (UNSD)
7. Statistical Office of the European Union (EUROSTAT)
8. University of Connecticut
9. World Health Organization (WHO)
10. The National Medical Products Administration (NMPA)
11. Indian Council of Medical Research (ICMR)
12. The Therapeutic Goods Administration
13. The Federal Institute for Drugs and Medical Devices (BfArM)
14. Pharmaceuticals and Medical Devices Agency (PMDA)
15. Agencia Nacional de Vigiloncia Sanitaria (ANVISA )
16. Ministry of Health, Labour & Welfare(MHLW)
17. Medicines and Healthcare Products Regulatory Agency (MHRA)
18. Centre for Pharmaceutical Administration Health Sciences Authority
19. Central Drug Standard Control Organization (CDSCO)
20. Organisation for Economic Co-operation and Development (OECD)
1. Bayer AG
2. Teva Pharmaceutical Industries Ltd.
3. Novartis AG
4. F. Hoffmann-La Roche Ltd.
5. Celgene Corporation
6. Acorda Therapeutics, Inc.
7. Sanofi
8. Actelion Pharmaceuticals (Johnson & Johnson)
9. EMD Serono (Merck KGaA)
10. AbbVie, Inc.
List of Companies Mentioned in the Report:
1. AbbVie
2. Achaogen
3. Actavis
4. Actelion
5. Affinium Pharmaceutical
6. AiCuris GmbH & Co. KG
7. Alcon
8. Alkem Laboratories
9. Allergan
10. Allied Pharma
11. Apotex
12. APP Pharmaceuticals
13. Aptalis Pharma
14. Aquapharm Biodiscovery
15. Cempra Pharmaceuticals
16. Cipla
17. Claris Lifesciences
18. Cornerstone Biopharma
19. Cornerstone Therapeutics
20. Corona Remedies
21. Eli Lilly
22. Gate Pharma
23. Gilead Sciences
24. GlaxoSmithKline (GSK)
25. Glenmark
26. GlycoVaxyn
27. Hetero
28. Hikma Farmaceutica
29. Hi-Tech Pharma
30. Hospira
31. Macleod Pharmaceuticals
32. Microlabs
33. Nalneva
34. Novartis
35. Novexel
36. Paratek Pharmaceuticals
37. Pfizer
38. Ranbaxy
39. Roche
40. Sagent Pharmaceuticals
41. Sandoz
42. Sanofi
43. Sequella
44. Shanghai MengKe Pharmaceuticals
45. Shionogi
46. SHIONOGI Co., Ltd.
47. Shire
48. Sidmak Labs
49. Solitaire Pharmacia
50. Specialised Therapeutics Australia
List of Organizations Mentioned in the Report:
1. European Medicines Agency (EMA)
2. Food and Drug Administration (FDA)
3. National Institutes of Health (NIH)
4. United Nations (UN)
5. United Nations Office on Drugs and Crime (UNODC)
6. United Nations Statistics Division (UNSD)
7. Statistical Office of the European Union (EUROSTAT)
8. University of Connecticut
9. World Health Organization (WHO)
10. The National Medical Products Administration (NMPA)
11. Indian Council of Medical Research (ICMR)
12. The Therapeutic Goods Administration
13. The Federal Institute for Drugs and Medical Devices (BfArM)
14. Pharmaceuticals and Medical Devices Agency (PMDA)
15. Agencia Nacional de Vigiloncia Sanitaria (ANVISA )
16. Ministry of Health, Labour & Welfare(MHLW)
17. Medicines and Healthcare Products Regulatory Agency (MHRA)
18. Centre for Pharmaceutical Administration Health Sciences Authority
19. Central Drug Standard Control Organization (CDSCO)
20. Organisation for Economic Co-operation and Development (OECD)
Download sample pages
Complete the form below to download your free sample pages for Multiple Sclerosis Drugs Market Report 2021-2031Download sample pages
Complete the form below to download your free sample pages for Multiple Sclerosis Drugs Market Report 2021-2031Do you have any custom requirements we can help you with?
Any specific country, geo region, market segment or specific company information?
Email us today, we can discuss your needs and see how we can help: sara.peerun@visiongain.com
Would you like a free report overview of the report of your choice?
If so, please drop an email to Sara Peerun stating your chosen report title to sara.peerun@visiongain.com
Visiongain’s reports are based on comprehensive primary and secondary research. Those studies provide global market forecasts (sales by drug and class, with sub-markets and leading nations covered) and analyses of market drivers and restraints (including SWOT analysis) and current pipeline developments. To find out more about our reports methodology, please email sara.peerun@visiongain.com
“Thank you for this Gene Therapy R&D Market report and for how easy the process was. Your colleague was very helpful and the report is just right for my purpose. This is the 2nd good report from Visiongain and a good price.”
Dr Luz Chapa Azuella, Mexico
American Association of Colleges of Pharmacy
American College of Clinical Pharmacy
American Pharmacists Association
American Society for Pharmacy Law
American Society of Consultant Pharmacists
American Society of Health-System Pharmacists
Association of Special Pharmaceutical Manufacturers
Australian College of Pharmacy
Biotechnology Industry Organization
Canadian Pharmacists Association
Canadian Society of Hospital Pharmacists
Chinese Pharmaceutical Association
College of Psychiatric and Neurologic Pharmacists
Danish Association of Pharmaconomists
European Association of Employed Community Pharmacists in Europe
European Medicines Agency
Federal Drugs Agency
General Medical Council
Head of Medicines Agency
International Federation of Pharmaceutical Manufacturers & Associations
International Pharmaceutical Federation
International Pharmaceutical Students’ Federation
Medicines and Healthcare Products Regulatory Agency
National Pharmacy Association
Norwegian Pharmacy Association
Ontario Pharmacists Association
Pakistan Pharmacists Association
Pharmaceutical Association of Mauritius
Pharmaceutical Group of the European Union
Pharmaceutical Society of Australia
Pharmaceutical Society of Ireland
Pharmaceutical Society Of New Zealand
Pharmaceutical Society of Northern Ireland
Professional Compounding Centers of America
Royal Pharmaceutical Society
The American Association of Pharmaceutical Scientists
The BioIndustry Association
The Controlled Release Society
The European Federation of Pharmaceutical Industries and Associations
The European Personalised Medicine Association
The Institute of Clinical Research
The International Society for Pharmaceutical Engineering
The Pharmaceutical Association of Israel
The Pharmaceutical Research and Manufacturers of America
The Pharmacy Guild of Australia
The Society of Hospital Pharmacists of Australia
Visiongain Pharma
Visiongain Pharma
Visiongain PharmaLatest Pharma news
Visiongain Publishes Automation in Biopharma Industry Market Report 2023-2033
The global Automation in Biopharma Industry market was valued at US$1,784.1 million in 2022 and is projected to grow at a CAGR of 5.7% during the forecast period 2023-2033.
20 March 2023
Visiongain Publishes eClinical Solutions Market Report 2023-2033
The global eClinical Solutions market was valued at US$8.03 billion in 2022 and is projected to grow at a CAGR of 13.09% during the forecast period 2023-2033.
17 March 2023
Visiongain Publishes Therapeutic Respiratory Devices Market Report 2023-2033
The global Therapeutic Respiratory Devices market was valued at US$59.49 billion in 2022 and is projected to grow at a CAGR of 8.02% during the forecast period 2023-2033.
15 March 2023
Visiongain Publishes Regenerative Medicine Market Report 2023-2033
The global Regenerative Medicine market was valued at US$ 50.37 billion in 2022 and is projected to grow at a CAGR of 18.40% during the forecast period 2023-2033.
10 March 2023
